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Kd;Diu 
 
‘MAs; khkiw Nakiwah nkt;th nwd;dpd;  
Ma tPlil Nthh;fs;kh dplh;fNs ay;yhy; 
Va Ntwpiy atUly; tPe;jplh jpaw;wj; 
J}a ed;kUe; Jiuj;jyh yhnkdr; nrhy;tha;” 
- Njiuah;. 
 
khdplg;gpwtp kl;LNk tPLNgW mila KbAk; cah;e;j 
gpwtpahFk;.  mjhtJ> tPLNgW miltNj khdplg; gpwtpapd; cah;e;j 
Nehf;fkhFk;. 
 
 ,jw;fhf Md;k rpj;jp> fharpj;jp ,tw;iw ngw;W Nghpd;g 
epiyapy; epw;f gofpath;fs; rpj;jh;fs;. ,jd; nghUl;L ml;lhq;f 
Nahfk; gapd;W> nka;Qhdk; ngw;W itj;jpak;> thjq;fspy; Njh;r;rp 
ngw;wth;fs; rpj;jh;fs;. 
 
 ,e;j tif cah;e;j Kaw;rpfspy; ,ilA+whf ,Uf;Fk; gpwtp> 
gpzp> Jd;gk; ,tw;iw ePf;fp> tPL Ngw;wpw;Fhpa mwk;> nghUs;> ,d;gk; 
vd;w Kg;gaidAk; ngw Ntz;Lk;.  ,jw;F ePz;l MASk;> Nehaw;w 
tho;f;ifAk;> ey;y cly; jj;Jt> kdj;jj;Jtq;fSk;> ey;tpidfSk; 
Ngutrpaq;fshFk;. 
 
rpj;j kUj;Jtk;: 
 
  ‘ahd; ngw;w ,d;gk; ngWf ,t;itafk;” -  vd;w vz;zj;Jld; 
rpj;jh; jk; khzhf;fh;fSk;;> kf;fSk; Nehaw;w tho;f;if thoTk;>  
rhjhuzkf;fs; kPJk; fopNghpuf;fk; nfhz;ljhYk; rpj;jh;fshy;> jkpo; 
nkhopapy; vOjp itf;fg;gl;Ls;s kUj;JtNk ‘rpj;j kUj;Jtk;” MFk;. 
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Neha;fs;: 
 ‘gfUeh yhap uj;J ehD}w;wp ehw;gj; njl;Lk; 
 GfYwg; ngz;zhd; NfhL nghUe;jpLk; nghd;ddha; Nfs;” 
- guuhr Nrfuk ;. 
rpj;j kUj;Jt mbg;gilapy; 4>448 Neha;fs; vd njhFj;J 
toq;fpAs;sdh;. 
 
NkYk;> gpzpfis tFf;Fk; KiwfSk; $wg;gl;Ls;sd. 
 
1. NehAz;lhFk; fhuzk; (cjhuzk;: thjk;> gpj;jk;> fgk;) 
2. Nehapy; fhZk; FwpFzq;fs; (cjhuzk;: Ruk;> nrhpahik> fhrk;) 
3. Nehia ghpfhpf;Fk; tiffs; (cjhuzk;: gl;bdp> fopr;ry;> the;jp>  
nea;KOf;F> njhf;fzk;) 
kUj;Jt ghpfhu Kiwfs;: 
 
 njd;nkhop kUj;Jt E}y; topahf ehk; mwpAk; kUj;Jt ghpfhu 
Kiwfs; %tifg;gLk;. 
 
1. tpz;zth; kUj;Jtk; 
2. khdpl kUj;Jtk; 
3. mRu kUj;Jtk; 
 
tpz;zth; kUj;Jtk;: 
 
 nkOFfs;> gw;gk;> nre;J}uk;> gjq;fk;> fl;L> fsq;F> Rz;zk;> 
rj;J Nghd;wtif kUe;Jfs; ifNjh;e;j kUj;Jth;fshy; nra;J 
Kbf;fg;gl;L ifahsg;gLfpd;wd. 
 
 ,q;F $wg;gl;Ls;s fl;L> fsq;F> Rz;zk;> rj;J> FUFspif 
Mfpait - gpw ,e;jpa Kiw kUj;Jtq;fspYk;> gpw ehl;L 
kUj;Jtq;fspYk; $wg;glhj - jkpo; kUj;Jtj;jpy; kl;LNk 
tpsf;fg;gl;Ls;s jdpr;rpwg;GfshFk;. 
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khdpl kUj;Jtk;: 
 
 Rurk;> rhW> FbePh;> fw;fk;> #uzk;> gpl;L> ,sfk;> vz;nza; 
Nghd;w tif kUe;Jfs; ek; ehl;L kf;fspd; md;whl tho;f;ifapy; 
,ay;ghf gad;gLj;jg;gl;L tUfpd;wd. 
 
mRu kUj;Jtk;: 
 
 ,it mDgtk; kpf;f kUj;Jth;fspd; cjtpAld; ifahsg;gLk; 
KiwfshFk;.   
mRu kUj;Jtk; NkYk; %d;W cl;gphpTfshfg; gphpf;fg;gLfpd;wd. 
 
1. mWit (cjhuzk;: mWit> fPwy;> ml;iltply;> njhf;fzk;> 
fl;Ljy;) 
2. mf;fpdp (cjhuzk;: Rl;bif> NtJ> xw;wlk;> nghl;lzk;> 
Gif) 
3. fhuk; (cjhuzk;: fhuk;> rPiy> fspk;G> nghb> ePh;> fsp> gir) 
 
‘A+fp itj;jpa rpe;jhkzp 800” E}ypy; $wpAs;sgb thj Neha;fs; 
80 MFk;.  mtw;wpy; xd;whd ‘cjpu thj RNuhzpjk;” vd;Dk; thj 
Neha; Ma;tpd; jiyg;ghf vLj;Jf; nfhs;sg;gl;Ls;sJ.  ,q;F cjpu 
thj RNuhzpj Neha; etPd kUj;Jtj;jpy; “RHEUMATOID ARTHRITIS” 
vd;Dk; NehAld; xg;gPL nra;ag;gl;Ls;sJ.  NkYk;> ‘Nkfehjp nkOF” 
cs;kUe;jhfTk;> ‘Kf;$l;L vz;nza;” ntspkUe;jhfTk; Njh;T 
nra;ag;gl;L cs;> ntsp Nehah;fisf; nfhz;L kUj;Jt Ma;T 
Nkw;nfhs;sg; gl;Ls;sJ.  
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AIM AND OBJECTS 
The disease UTHERA VATHA SURONITHAM affects about 1% of 
the total population, causing disabilities and deformities in all over the 
world. 
Out of them females are frequently affected three to four times 
more than that of male.  Our country  is the one which is constructed by 
the joint families and is praised by other countries also. In this females 
get more responsibilities for the cooperation and managements of family 
events.  But when  the home makers are affected by the Uthera Vatha 
Suronitham  (Rheumatoid Arthritis) the whole memebers of the family 
are suffered by lot of inabilities in their routine life. 
Rheumatoid arthritis is the one which is to be evaluated for 
peculiar conditions and searching for the cure with proper medicines. 
Regarding this aim, the disease UTHERA VATHA SURONITHAM  
has been selected  and clinical trial has been done with the internal 
medicine Meganathee Mezhugu (Nkfehjp nkOF) and the external 
medicine Mukkuttu Ennai (Kf;$l;L vz;nza;) 
 
¾ To collect authentic measures and review the ideas mentioned in 
ancient siddha literature about the disease. 
¾ To study the clinical features of the disease UTHERA VATHA 
SURONITHAM with correlation of RHEUMATOID ARTHRITIS in 
modern aspect. 
¾ To review the altered Tridosha or Mukkutram and changes in the 
physiology as per siddha aspect. 
¾ To study the disease UTHERA VATHA SURONITHAM on the basis 
of Udal thathu, paruva kaalam, food, taste, age, sex,socio-
economic status, ennvagai thervu, neerkuri and neikuri. 
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¾ To expose the unique diagnostic procedure mentioned in siddha 
literature for the disease UTHERA VATHA SURONITHAM. 
¾ To diagnose the disease on the basis of modern parameters. 
¾ To have a detailed analysis to prove the clinical efficacy of the 
drugs through the pharmacological and biolchemical analysis. 
  
The work is to be carried out by having a clinical trial by using 
Meganathee Mezhugu (Nkfehjp nkOF) as internal drug and 
Mukkuttu Ennai (Kf;$l;L vz;nza;) as external drug on 20 
inpatients  and 20 outpatients with the disease UTHERA VATHA 
SURONITHAM. 
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SIDDHA ASPECTS 
 
 ‘ghug;gh G+jike;J kz;ePh; NjA  
ghpthd thfha ike;jpdhNy”     
                                              -  rjf ehb 
 
 G+jq;fs; Ie;J MFk;.  mit kz;> ePh;> jP> fhw;W> Mfhak; 
vd;git. 
  
‘epyk; jPePh; tsp tpRk;Ngh ile;Jq; 
 fye;j kaf;fk; cyfk; Mjypd;” 
                 -  njhy;fhg;gpak;: nghUsjpfhuk; - 635 
 
cyfk; Ie;J G+jq;fshy; MdJ. 
 
‘kz;bdpe;j epyDk; 
epyNde;jpa tpRk;Gk; 
 tpRk;GijtU tspAk; 
tspj;jiy,a jPAk; 
 jPKuzpa ePUk; vd;whq;F 
Ik;ngUk; G+jj; jpaw;if”   
                                       -  GwehD}W  - 2 
 
gQ;r g+jq;fspd; Nrh;f;ifNa cyfkhfTk;> rPtuhrpfshfTk;> 
cyfj;jpd; nghUs;fshfTk; Njhd;wpAs;sd. 
 
rpj;j kUj;Jtk; jj;Jtq;fs; my;yJ nka;fis mbg;gilahff; 
nfhz;lJ.  nkhj;jk; ehd;F NfhbNa ehw;gj;njl;lhapuj;J IE}W 
(4>00>48>500)  jj;Jtq;fs; cs;sd.  mtw;iw RUf;fp 96 jj;Jtq;fshf 
tFj;Js;sdh; rpjjh;fs;. njhz;Z}w;whW jj;Jtq;fspy; Ie;J 
G+jq;fSk; Kf;fpakhditfshFk;. 
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gQ;r G+jq;fs; clypy; Ie;J nghwpfshfTk;> mtw;wpd; 
Gyd;fshfTk; Neubahf njhlh;G nfhz;Ls;sd.  Ie;JG+jq;fspd; 
Nrh;f;ifapy; Vw;gLk; khw;wq;fNs MWRitfs; Njhd;wTk; 
fhuzkhfpd;wd. 
 
 gQ;r g+jq;fspy;  thA> jP> ePh; vd;git KiwNa tsp> moy;> Iak; 
vd;Dk; caph; jhJf;fshf clypy; jj;jk; nray;fisg; Ghpfpd;wd. 
 
tsp> moy;> Iak; %d;Wk; jk; ,aw;if mstpy; ,Uf;Fk;NghJ 
‘caph;jhJf;fs;” vd;wiof;fg;gl;L> ehbahy; czug;gLfpd;wd. 
 
‘toq;fpa thjk; khj;jpiu nahd;whfpy; 
 joq;fpa gpj;je; jd;dp yiuthrp  
moq;Fq; fge;jh dlq;fpNah fhNyhby; 
gpoq;fpa rPtw;F gprnfhd;W kpy;iyNa” 
       - Fzthfl ehb. 
‘nka;asT thjnkhd;W 
Nky;gpj;j Nkhuiuahk; 
 Iaq; fhnyd;Nw mwp” 
- fz;Zrhkpak;. 
 
tsp> moy;> Iak; jk; ,ay;igtpl;L khWk;NghJ mitNa 
‘Kf;Fw;wq;fs;” my;yJ ‘jphpNjhlq;fs;” vd;wiof;fg;gl;L Neha;fSf;F 
fhuzkhfpd;wd. 
‘kpfpDk; FiwapDk; Neha;nra;Ak; E}NyhH                                                     
 tspKjyh vz;zpa %d;W” 
         - Fws;. 
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cjpu thj RNuhzpjk; 
 
tsp (thjk;) jd; mstpy; kpFe;jpUf;Fk; NghJ clypy; 
thjNeha;fs; Njhd;Wfpd;wd. 
 ‘A+fp itj;jpa rpe;jhkzp” E}ypd;gb ‘vd;dNt thjkJ 
vz;gjhFk;” vd;W ghbdhYk; mitfspd; ngah;fisAk;> 
Fzq;fisAk; $Wk;NghJ vz;gj;ije;J tiffisf; $wpAs;shh;.  
mtw;wpy; xd;W ‘cjpu thj RNuhzpjk;’; MFk;. 
 
cjpu thj RNuhzpjk; ,ay;G: 
 thjk; clypd; xt;nthU gFjpapYk; nray;Ghpe;jhYk;> cjpu thj 
RNuhzpjk; vd;Dk; thjNeha;  Kf;fpakhf clypd; vy;yh rpwpa kw;Wk; 
nghpa %l;LfspYk; gw;;wp typ> tPf;fk;> nray;gLj;j rpukk;> kd Ntjid> 
rypg;G> grpapd;ik Mfpa ,ay;Gfisf; nfhz;ljhf cs;sJ.  
 
Neha; tUk; top: 
  
 nghJthf Neha;fs; Njhd;wf; fhuzq;fs; gy ,Ug;gpDk; 
mtw;iw ehd;F Kf;fpa gphpTfshf gphpj;Jf; nfhs;syhk;. 
 
1. czthjp nray;fs; 
2. ,r;rhjp nray;fs; 
3. mz;l gpz;l xw;Wik 
4. Co;tpidfs; 
 
czthjp nray;fs;: 
 ‘jhndd;w frg;NghL Jth;;g;G iug;G 
  rhjfkha; kpQ;RfpYQ; rikj;j td;dk;; 
Mnkd;w thwpdJ nghrpj;jyhYk;  
Mfhaj; NjwyJ Fbj;jyhYk;  
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khndd;w gfYwf;f kpuhtp opg;G  
gl;bdpNa kpf TWjy; ghu nka;jy; 
Njndd;w nkhopahh; Nkw;rpe;ij ahfpy; 
rPf;fpukha; thjkJ nrdpf;Fe;jhNd.”  
- A+fp itj;jpa 
rpe;jhkzp ghly;. 
 
‘njhopy; ngWifg;Gf; fhu;j;jy; Jth;j;jy; tpQ;RfpDQ; NrhWk; 
gioajhk; tuF kw;iwg; ige;jpid aUe;jpd jhYk; 
vopy; ngwg; gfYwq;fp ,utpdp Ywq;fhj jhYk; 
kio epfh; Foyp dhNy thjq; Nfhgpf;Fe; jhNd” 
     - A+fp itj;jpa rpe;jhkzp. 
frg;G> Jth;g;G> fhu;g;G gjhh;j;jq;fis kpFjpahf cz;zy;> 
gioa NrhW> tuF> jpid cz;zy;> gfypy; J}q;fp ,uT tpopj;jy; 
Mfpa fhuzq;fshYk; thjk; kpFk;. 
 
‘tsp jU fha;fpoq;F tiutpyh japyy; Nfhio 
Ksp japh; Nghd;kpFf;F Kiwapyh Tz;b Nfhly;  
Fsph;jU tspapw; Nwfq; Fdpg;Gw Tyty; ngz;bu;  
Fspj;jU Kaf;fk; ngw;Nwhu; fb nray; fUtp ahkhy;.” 
- rghgjp ifNaL. 
 thjf; Fw;wj;ij kpifg; gLj;jf; $ba fpoq;F tiffs;> 
Fspu;r;rpia juf; $ba gjhh;j;jq;fs; kpFjpahf cz;zy; Fspu;e;j 
fhw;wpy; ,Uj;jy;> kioapy; eidjy;> gdpf;fhw;W NkNy tpOjy;> kiyg; 
gpuNjrq;fspy; trpj;jy; kw;Wk; guk;giuapd; fhuzkhfTk; Njhd;Wk;. 
 
‘fhyq;fz; khwp Az;Zq; fhhpaj; jhYe; jz;zPh;  
rhyNt aUe;jpd jhYk; re;jpap Yl;fhh;e; jhYk; 
Nfhykhk; Gspg;G nea;iaf; Fiwtw tUe;jp dhYk; 
thythu; Kiyey; yhNs thjKw;g tpf;Fq; fhNz.”  
- A+fp itj;jpa rpe;jhkzp. 
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,r;rhjp nray;fs;: 
 
,akk;> epakk; vDk; gof;ftof;fq;fs;> tpjpfspy; jtWtjhy; 
Neha;fs; Njhd;Wk;. 
 
‘vd;dNt thje; jhndz;g jhFk; 
,fj;jpNy kdpjh;fSf; nfa;JkhW 
gpd;dNt nghd; jidNa NrhuQ; nra;J 
ngupNahh;fs; gpuhkziuj; J}lzpj;Jk; 
td;dNj tr;nrhj;jpw; NrhuQ; nra;J 
khjh gpjh FUit kwe;j Ngh;f;Fk; 
fd;dNt Ntjj;ij epe;ij nra;jhy;; 
fhaj;jpw; fye;jpLNk thje; jhNd” 
- A+fp itj;jpa rpe;jhkzp  
‘nta;apypy; elf;ifahYk; kpfj;jz;zPh; Fbf;ifahYk; 
nra;apio kfspiur; Nrh;e;jDg tpf;ifahYk; 
igaNdh z;ikahYk; ghfw;fha; jpd;ifahYk; 
ijaNythjNuhfk; rdpf;Fnkd; wwpe;J nfhs;Ns”  
- Njiuah; thflk;. 
 #hpa ntg;gj;jpy; mjpf njhiyT elf;ifahYk;> mjpfjz;z;Ph; 
Fbf;ifahYk;> mjpf msT ghfw;fha; rhg;gpLtjhYk; tsp Neha;fs; 
Njhd;Wk;. 
 ‘fhzNt kpfTz;lhYq; fUJgl;bdp tpl;lYk; 
  khdid ahh;fz; Nkhfkpwf;fpD kpFe;jpl;lhYk; 
 Mzt kyq;flik aq;qNd tplhjjhYk; 
  thDjd; kley;yhNs thjq;Nfh gpf;Fq;fhNz.” 
- A+fp itj;jpa rpe;jhkzp  
 mjpf msT cz;zy;> gl;bdp fplj;jy;> Mztk; mjpfhpj;jy; 
Mfpatw;why;  thjNeha;fs; Njhd;Wk;. 
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‘ghhpdpw; gag;gl;lhYk; gyUld; Nfhgpj;jhYk; 
  fhnudf; fUfpNahbf; fOkuj; Juj;jpdhYk; 
 Vh;ngW jdJ neQ;rpd; kpfj;Jf;f kilj;jpl;lhYk; 
  ghhpa fhw;wpdhYk; glhpDk; thjq;fhZk;.” 
- A+fp itj;jpa rpe;jhkzp  
gak;> vy;NyhhplKk; Nfhgk; nfhs;sy;> kpFjpahf Xly;> kpFe;j 
Jf;fk;> jpdKk; clypd;Nky; fhw;Wg;gly; Nghd;wtw;why; thjk; 
Njhd;Wk;. 
 
mz;l gpz;l xw;Wik: 
  
 ‘mz;lj;jpy; cs;sNj gpz;lk; 
 gpz;lj;jpy; cs;sNj mz;lk; 
 mz;lKk; gpz;lKk; xd;Nw  
 mwpe;J jhd; ghh;f;Fk; NghNj”  
- rl;lKdp Qhdk;. 
mz;lj;jpy; cs;s Nfhs;fs; kw;Wk; el;rj;jpuq;fspd; xt;nthU 
mirTfSk;> fjph;tPr;RfSk; clypYk;> kdjpYk; Kf;fpa khw;wq;fis 
cz;lhf;Ffpd;wd. vdNt> ,g;gpugQ;rj;jpy; G+kpf;F neUf;fkhf cs;s 
#hpaf; FLk;gj;ijr; Nrh;e;j 9 Nfhs;fs;> 27 el;rj;jpuq;fspd; 
,af;fq;fis thdtpay;gbAk;> Nrhjpltpay; gbAk; czh;e;J> clYld; 
xg;gPL nra;J Neha;f;Fhpa fhuzq;fis mwpayhk;. 
 
 cjhuzkhf>  
  ‘Mjpiu guzp fhh;j;jpif  
   Mapy;a Kg;G+uq; Nfl;il 
jPJW tprhfQ; Rthjp 
rpj;jpiu kfk; <uhwpy; 
khjdq; nfhz;lhh; jhuhh; 
gopeilg; gl;lhh; kPshh; 
gha;jdpw; gLj;jhh; Njwhh; 
ghk;gpd; tha; NjiujhNd” 
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‘thjth;jd fhyNkNjh ntd;dpy; 
  kUTfpd;w Mdp fw;fl khjk; 
 Mjidg; grpNahL fhh;j;jpif jd;dpy; 
  mlUNk kw;w khjq;fs; jd;dpy; 
 NghfNt rkpf;fpdpw; fhy khFk;” 
-  A+fp rpe;jhkzp 
  
tsp NehahdJ Mdp Kjy; fhh;j;jpif khjq;fspy; mjpfkhf 
fhzg;gLk;. 
  
‘gJkj;ij G+f;f itf;Fk; ghDkpff;fhAk; 
 KJntdpypw;G tpw;wPePH; Kw;Wk; - fJnkd 
 tw;Wk; fgkf;Fk; thAkpFk; tho;khe;jh;f; 
Fw;w eypf;Nfjpnjd; NwhJ.” 
- rpj;j kUj;Jthq;fr; RUf;fk;. 
KJNtdpw; fhyj;jpy; #hpa ntg;gj;jpd; fhuzkhf ngUk; 
thupahd ePh; Mtpahf;fg;gl;L cyfj;jpy; twl;rp epyTk;.  mJ Nghy 
ekJ clypYk; twl;rp Vw;gl;L tsp Neha; tUtjw;F fhuzkhfpd;wJ. 
 
 Nrhjplk; gQ;r gl;rp 
Jyq;fpa ruE}y; khh;f;fk; 
NfhjW tfhu tpj;ij 
FWKdp XJ ghly; 
jPjpyhf; ff;fp \q;fs; 
nrg;gpa fd;k fhz;lk; 
<njyhk; fw;W zh;e;Njhh; 
,th;fNs itj;jpa uhth;” 
      - gjpndz; rpj;jh; ehbE}y;. 
  
  ,t;thW kUj;Jtd; mwpe;jpUf;f Ntz;ba E}y;fspy; 
Kjd;ikahf Nrhjplj;ij $Wfpd;wdh; rpj;jh;fs;. 
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Co;tpid: 
fle;j gpwtpapd; jPtpidfshYk;> Kd;Ndhh;fspd; fd;k 
tpidfshYk;  Neha;fs; Njhd;Wfpd;wd.  gpw kUj;Jt Kiwfspy; 
njhpahj fhuzq;fshy; Njhd;Wk; Neha;fis ,g;gphptpy; mlf;fyhk;. 
 
 ‘me;jzh; fw;G khjh; mUspa rhgj;jhYk;  
  Ke;jpa tpidahYk; Kjph;fu;g;g Nkfj;jhYk; 
 rpe;ijapw; nfhLikahYk; rptFU epe;ijahYk; 
  njhe;jkhk; tpahjpahYk; Njhd;wpLk; #iyjhNd” 
- mfj;jpah; 
‘E}nyd;w thjk; te;jtif jhNdJ 
Jz;ikaha;f; fd;kj;jpd; tifiaf; NfS 
fhypNy Njhd;wpaJ fLg;g NjJ 
iffhypy; Klf;fpaJ tPf;f NkJ 
NfhypNy glfpd;w tpUl;r khd 
Foe;ij kue;jd;id ntl;ly;Nky; Njhy; rPty; 
ehypNy rPtnre;J fhy; Kwpj;jy; 
ey;y nfhz;b jioKwpj;jy; eypj;jy; jhNd” 
    - mfj;jpah; fd;k fhz;lk; -300  (ghly; 56) 
 
cjputhj RNuhzpjk; - FwpFzq;fs;: 
 
‘A+fp itj;jpa rpe;jhkzp” E}ypd;gb> 
 
 ‘itfpjkha;f; fZf;fhY Koq;fhy; jhDk; 
  kw;flQ; re;JGw tbAk; tPq;fpr; 
 nra;fpjkhQ; rpWtpuy;fs; kpfTk; nehe;J  
rpe;ijjL khwpNa rypg;Gz; lhFk; 
 igfpjkhk; igj;jpaj;jpy; thj kpQ;rpg; 
ghukha; cw;gtpj;J moYz; lhFk;  
ca;fpjkha; mrdkJ jhDk; Ntz;lh  
cjputhj RNuhzpjj; Jzh;r;rp ahNk” 
- A+fp itj;jpa rpe;jhkzp 800. 
14 
 
 
nghUs;: 
¾ fZf;fhy;> Koq;fhy;> re;Jfs; (Joints);> Gwtb (Dorsum of Foot) 
,itfspy; tPq;Fk;.(Swelling in Ankle joint, Knee joint, Dorsum of foot and 
other joints) 
¾ rpWtpuy;fs; kpfTk; Nehia (Pain) gpwg;gpf;Fk;. (Pain in fingers that is 
Interphalangeal joints) 
¾ rpe;ij jLkhWk;. (Mental confusion) 
¾ rypg;Gz;lhFk;. (Easy fatiguability) 
¾ thjk; kpQ;Rk;. (Increased Vatham ) 
¾ moy; cz;lhFk;. (Increased Pitham) 
¾ grpapd;ik cz;lhFk;. (Loss of appetite) 
 
‘guuhr  Nrfuk; E}ypd;” gb> 
 
‘nghh;rPNj Tjpu thj RNuhzpj Koq;fhy; jhDk; 
nghw;fizf; fhYk; re;Jk; Gwtb jhDk; tPq;fp 
ew;fZ tpuy;f ndhe;J eLg; gapj;jpa thjj;jpy;  
cw;gtf; FzK Kz;lh KWE}ypw; nrhd;d jhNk.” 
 - guuhrNrfuk;. 
nghUs;: 
¾ Koq;fhy;> fZf;fhy;> re;Jfs;> Gwtb(Dorsum of Foot) 
Mfpait tPq;Fk;. 
¾ tpuy; fZf;fs; NjhWk; typAz;lhFk;. (Pain in Inter 
Phalangeal Joints) 
¾ gapj;jpa thjj;jpy; fhZk; Fzq;fSk; (Osteoporosis) 
Njhd;Wk;. 
 cjputhj RNuhzpjj;jpy; fhzg;gLk; FwpFzq;fs; etPd 
kUj;Jtj;jpy; $Wk; Rheumatoid Arthritis Nehapd; 
FwpFzq;fSld; ngUk;ghYk; xj;Js;sd.  
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Kf;Fw;w ,ay;: 
 tsp> moy;> Iak; jj;jk; epiyapy; $bAk;> Fiwe;Jk; 
Njhd;Wk; NghJ Fw;wq;fshf ghpzkpf;fpd;wd. 
 
tsp: 
 tsp vd;gij fhw;W> Cij> thjk;> fhy; vd;Wk; $Wth;. 
twl;rpAk;> ,af;fKk; nfhz;lJ. 
thOkplk;: 
 mghdk;> kyk;> ,lfiy> ce;jpapd; fPo; %yk;> fhkf;nfhb> ,Lg;G 
vYk;G> Njhy;> euk;Gf; $l;lk;> fPy;fs;> kapHf;fhy;fs;> Cd; Mfpa 
,lq;fspy; tho;tjhFk;. 
 
tspapd; ,aw;ifg;gz;G: 
 Cf;fKz;lhf;fy;> %r;R tply;> %r;R thq;fy;> kyk; Kjypa 
gjpdhd;F Ntfq;fis ntspg;gLj;jy;> rhuk; Kjypa VO 
clw;jhJf;fSf;Fk; xj;j epfo;r;rpiaj; juy;> Ik;nghwpfl;F td;ikiaf; 
nfhLj;jy; Mfpatw;wpy; clw;Fj; JizGhpjyhk;. 
 
tsp clypy; nra; njhopy;: 
 cly; Nehjy;> Fj;jy;> euk;G Kjypad Fd;wy;> eLf;fy;> twl;rp> 
G+l;L eOty;> kyk;> rpWePH Kjypad jPa;jy; my;yJ milgLjy;> 
ePHNtl;if> Njhy;> fz;> kyk;> ePH Kjypad fWj;Jf; fhzy;> vr;RitAk; 
JtHg;ghapUj;jy; my;yJ JtHg;ghf tha; eP&wy;. 
 
tspapd; gphpTfs;: 
 ,J xd;whapUg;gpDk; jd; ,lk;> njhopy; Kjypatw;why; gj;J 
tifg;gLk;. 
1. capHf;fhy; (gpuhzd;) - %r;R tpLjYk;> thq;FjYk; nra;Ak;. Grpf;Fk; 
gyg;gy czTfisAk; nrhpf;fg;gz;Zk;. 
2. fPo;Nehf;Fq;fhy; (mghdd;) - fPo;Nehf;fp kyryj;ijj; js;Sk;> 
Mrdthiar; RUf;Fk;> md;drhuj;ijr; Nru Ntz;ba ,lq;fspy; 
NrHg;gpf;Fk;. 
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3. guTfhy; (tpahdd;) - cWg;Gfis ePl;lTk;> klf;fTk; nra;J> ghprq;fis 
mwpAk.; cz;Zk; cztpd; rhuj;ij mt;tt;tplq;fspy; NrHg;gpj;J cliyf; 
fhf;Fk;. 
4. Nky;Nehf;Fq;fhy; (cjhdd;) - cztpd; rhuj;ijf; $bapUe;J> mij 
mq;fq;Nf epWj;Jk;;. mij ntspg;gLj;jpAk;> fyf;fpAk; tUjy; nra;Ak;. 
5. eLf;fhy; (rkhdd;) - Nkw;$wpa ehd;F thAf;fisAk; kpQ;rnthl;lhky; 
rkg;gLj;Jk;. mWRitfisAk;> jz;zPH> md;dk; Mfpatw;iwAk; rkg;gLj;jp> 
clypnyy;yhk; NrUk;gb nra;Ak;. 
6. ehfd; - mwpitnaOg;Gk;> fz;fisj; jpwf;Fk;gb nra;Ak;. fz;fis 
,ikf;Fk;gb nra;Ak;. kapHfisr; rpypHf;fr; nra;Ak;. 
7. $Hkd; - nfhl;lhtp tplg;gz;Zk;. gyj;ij cz;Lgz;Zk;. fz;fisj; 
jpwf;fTk; %lTk; gz;Zk;. cyfj;jpYs;s nghUl;fis vy;yhk; fz;fSf;Ff; 
fhz;gpf;Fk;. fz;fspdpd;Wk; ePiu tpog;gz;Zk;. 
8. fpUfud; - ehtpYk;> ehrpapYk; frpit cz;lhf;Fk;. kpf;f 
grpiaAz;lhf;Fk;. xd;iw epidj;jpUf;fr; nra;Ak;. Jk;kiyAk; ,UkiyAk; 
cz;lhf;Fk;. 
9. Njtjj;jd; - Nrhk;giyAk; cly; Kwpj;jiyAk; cz;lhf;Fk;. J}q;fp 
vOe;jpUf;Fk; NghJ maHr;rpia cz;lhf;Fk;. fz;iz gy ,lq;fspy; Xl;b 
cyhTtpf;Fk;. kpf;f Nfhgj;ij cz;L gz;Zk;. 
10.jdQ;nrad; - ,J %f;fpypUe;J jbj;J> clk;G KOikAk; tPq;fg;gz;Zk;. 
fhjpy; fly;Nghd;wpiur;rypl;L> ,we;J tpbd; fhw;nwy;yhk; ntspg;gl;l 
gpd;dH %d;whtJ ehspy; jiyntbj;j gpd; jhd; NghFk;. 
 
cjpu thj RNuhzpjj;jpy; tsp: 
 
 ghjpg;gile;j thAf;fs; FwpFzq;fs; 
1. mghdd; kyr;rpf;fy; 
2. tpahdd; %l;Lfspy; tPf;fk; 
3. rkhdd; grpapd;ik 
4. Njtjj;jd; J}f;fkpd;ik 
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moy;: 
 ntg;gKk; $HikAk; cilaJ. gpj;jk; vdTk; miof;fg;gLk;. 
moy; thOkplk;: 
 gpq;fiy> gpuhzthA> ePHg;ig> %yhf;fpdp> ,Ujak;> jiy> ce;jp> 
nfhg;G+o;> ,iug;ig> tpaHit> ehtpY}Wfpd;w ePH> nre;ePH> rhuk;> fz;> Njhy; 
vd;Dkpit moy; thOkplq;fshFk;. <jd;wp> 
 ‘gphpe;jpLk; gpj;jk; Nguhk; ryj;jpdpy;”  vdj; jpU%yUk;> 
 ‘Nghnkd;w gpj;jj;Jf; fpUg;gplNk Nfsha; 
  Nguhd fz;lj;jpd; fPojhFk;” 
vd A+fpKdptUk; $Wfpd;wdH. 
moypd; ,aw;ifg; gz;G: 
 ‘grpjhfk; Xq;nfhspfz; ghHitgz; lj;J 
  Urpnjhp rj;jpntk;ik tPuk; - crpj 
  kjp$Hj;j Gj;jptdg; gspj;Jf; fhf;Fk; 
  mjpfhhp ahq;fh doy;.” 
- kUj;Jt jdpg;ghly;fs; 
moypd; njhopy;: 
 clypy; ntg;gKz;lhjy;> nre;epwk; my;yJ kQ;rs; epwk; Njhd;wy;> 
tpaHj;jy;> kaf;fk; Vw;gly;> rPw;wk;> tzf;fkpd;ik> mirtpd;ik> epidT> 
ntwp> nkypT> vhpT cz;lhjy;. vr;RitAk; ifg;ghfNtDk; Gspg;ghfNtDk; 
fhZjy;. 
moypd; gphpTfs;: 
 moy;> jd; ,lk;> njhopy; Ntw;Wikahy; Itifg;gLk;. mit: 
1. Mf;fdy; (mdw;gpj;jk;) - jPapd; gz;GilaJ. jPapd; Fzj;ij kpFjpahfg; 
ngw;W> ePh; tbtKs;s nghUs;fis twsr;nra;J> cz;l czTg; 
nghUs;fisr; nrhpf;Fk;gb nra;Ak;. 
2. tz;z vhp (,uQ;rfk;) - nre;ePiu kpFjpg;gLj;Jk; gz;GilaJ. 
cztpypUe;J cz;lhd rhw;Wf;F nre;epwj;ijj; jUfpwJ. 
3. Mw;wyq;fp (rhjfk;) - epiwNtw;Wk; gz;GilaJ. mwpT> Gj;jp> gw;W 
,tw;iwf; nfhz;L tpUg;gkhd njhopiyr; nra;J Kbf;Fk;. 
4. xs;nshspj;jP  (gpuhrfk;) - NjhYf;F xspiaj; jUk; gz;GilaJ. 
5. Nehf;foy; (MNyhrfk;) - fz;fSf;Fg; nghUs;fisj; njhptpf;Fk; 
gz;igAilaJ. 
18 
 
 
cjputhj RNuhzpjj;jpy; moy;: 
 ghjpg;gile;j moy; FwpFzq;fs; 
1. mdw; gpj;jk; grpapd;ik
2. ,uQ;rfk; ntSg;G
3. rhjfk; %l;Lfis nray;gLj;j ,ayhik 
 
Iak;: 
 jd;ik nea;g;G> ke;jk;> tOtOg;G> nkd;ik> jpz;ik Mfpa 
jd;ikfisAilaJ. 
Iak; thOkplk;: 
 rkhdthA> RopKid> ntz;zPH (tpe;J)> jiy> Mf;fpid> ehf;F> 
cz;zhf;F> nfhOg;G> kr;ir> FUjp> %f;F> khHG> euk;G> vYk;G> %is> 
ngUq;Fly;> fz;> fPy;fs; vd;Dk; ,itfs; Iak; thOk; ,lq;fshFk;. 
 
Iaj;jpd; ,aw;ifg; gz;G: 
 epiyj;jy;> nea;g;G> fPy;fspy; mikg;gpd; fl;Lfs;> nghiwAilik (grp> 
ePHNtl;if> Jauk;> fyf;fk;> ntg;gk; ,itfisg; nghWj;Jf; nfhs;Sjy;) 
Mfpa ,it Iaj;jpd; ,aw;ifg; gz;Gfs;. 
Iaj;jpd; njhopy;: 
 nea;g;G> gUj;jy;> td;ik> nrwpT> jz;ik> fPy;fs; njhopy; 
GhpahjpUj;jy;> cly; ntSj;jy;> Cz; tpiutpy; nrhpahik> kpFJ}f;fk;> 
ehtpy; ,dpg;Gr; Rit Njhd;wy;> Njhy;> fz;> kyk;> rpWePH ntz;zpwkiljy;> 
njhopy; Ghptjpy; $Hikapd;ik Mfpa ,it Iaj;jpd; njhopy;fshFk;. 
Iaj;jpd; gphpTfs;: 
 thOk; ,lk;> njhopy; ,tw;wpd; mbg;gilapy; Iak; Itifg;gLk;. 
1. mspiaak; (mtyk;gfk;) - jd; ,aw;if nefpo;r;rpj; jd;ikiaf; nfhz;L 
kw;w ehd;F tif Iaq;fl;Fk; gw;Wf; Nfhlhf cs;sJ. 
2. ePHg;gpiaak; (fpNyjfk;) - cz;zg;gl;l czTg; nghUs;> ePH 
Kjypaitfis <ug;gLj;jp nkj;njdr; nra;Ae; njhopiyg; GhpAk;. 
3. Ritfhizak; (Nghjfk;) - cz;Zfpd;w nghUl;fspd; Ritfis 
mwptpf;Fe; njhopiyr; nra;Ak;. 
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4. epiwitak; (jw;gfk;) - ,J jiyapdpd;W ,Ufz;fSf;Fk; FspHr;rpiaj; 
jUk;. 
5. xd;wpiaak; (re;jpfk;) - ,J fPy;fspy; epd;W ,aw;ifaha; vy;yhf; 
fPy;fisAk; xd;Nwhnlhd;W nghUj;jpj; jsur; nra;J nfhz;bUf;Fk;. 
 
cjpu tsp RNuhzpjj;jpy; Iak;: 
 ghjpg;gile;j Iak; FwpFzq;fs; 
1. fpNyjfk; grpapd;ik 
2. re;jpfk; %l;Lfspy; typ> tPf;fk; 
 
clw;fl;Lfs; 
clw;jhJf;fs; vdTk; miof;fg;gLk;. ,it VO tifad. 
1. rhuk;: 
 cliyAk;> kdijAk; Cf;fKwr; nra;tJ. 
 VO clw;fl;Lfspy; xd;whd rhuk; ,urk;> rhW vd;Wk; 
miof;fg;gLk;.  cz;l czT xUtpj ePh;kakhf khw;wg;gl;L 
md;durkhfpwJ(Digestive fluid).  ,iuFlypy; ,uradpfshYk;> 
khradpfshYk; (Intestinal villli, Lymphatics) cwpQ;rg;gl;L cly; 
urkhf(Plasma) khw;wg;gl;L FUjpapy; fyf;fpwJ. 
 trhePh;: FUjpapYs;s md;durk; jpRf;fSf;F kNrhh;g;gpj;jJ> 
jrpuq;fspdpd;W frpe;J nrd;W jpRf;fis Nghlzpf;fpwJ.  ,f;frpTePh; 
trhePh; (Plasma) vdg;gLk;. 
 tghePh;: jpRurj;jpypUe;J cwpQ;rg;gl;L Kjd;ikahf rpwg;Gw;W 
tpsq;FtJ tghePuhFk;.  tghePh; khradpfspd;(Lymphatic) %yNk  
Row;rpailAk;.  ,r;Row;rpapy; tpA+ghtuf tpyq;fs; (Lymphoid follicles)> 
khradp Foy;fs; (Lymph vessels)> tghfoiyfs;(Lymph glands)> 
tghntz;tpyq;fs; (Lymphocytes) Mfpait mlq;Fk;. 
 tghePhpy; FUjptrhePhpy; (Plasma) cs;sij tpl fhypfg; 
nghUs;fs; (Proteins) Fiwthf cs;sd. 
 tghfoiyfspy; jplg; nghUs;fisAk;> te;ijfisAk; epWj;jp 
mopf;fg;gLfpd;wd(Phagocytosis). 
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 In Utheraa Vatha Suronitham, the HLA-DR4 Antigen from the plasma 
has special affinity for synovial tissue.  So, in the joints the early changes are as 
follows:  
o Increased Vascular congestion 
o Proliferation of synoviocytes 
o Infiltration of synovial layers by polymorphs, lymphocytes, 
plasma cells. 
o Thickening of capsular structure 
o Villous formation of synovium 
o Cell-rich effusion into joints and tendon sheaths 
 
cjpu thj RNuhzpjj;jpy; rhuk; kpf Kf;fpakhf ghjpf;fg;gLfpwJ.  
,q;F A+fp Kdpth; gad;gLj;Jk; ‘RNuhzpjk;” vd;Dk; thh;j;ij VO 
clw;fl;Lfspy; rhuj;ijr; rhh;e;j Synovial fluid - I Fwpg;gjhf 
nfhs;syhk;. 
In this diseased condition Polymorphs, Lymphocytes, Plasma cells are 
increased and Lymphglands are enlarged and Macro[hagic action is also 
modified. 
 
2. nre;ePH: 
 mwpT> td;ik> xsp> nrUf;F> xyp ,itfis epiyf;fr; 
nra;tJ. 
 ,j; jhJtpy; nre;epw capuZf;fs; (RBC)> ntz;zpw 
mZf;fs;(WBC)> FUjpj;jhJ caph; mZf;fs; (Platelets)> cly; caph;r; 
rj;Jfs; (Vitamins)> cg;Gfs; (Minerals) Nghd;wit ,Uf;fpd;wd. 
 cjputhj RNuhzpjj;jpy; RBC, WBC ghjpf;fg;gLfpd;wd. 
 nrt;tpy tz;ly Ntfk; (E.S.R).mjpfhpj;Jf;fhZk;. 
 Haemoglobin msT Fiwe;J fhzg;gLk;.  
 Lymphocytes mjpfhpj;Jf; fhzg;gLk;.   
 NkYk;> B-Lymphocyte - ypUe;J gpwf;Fk; Anti Ig G Antibody 
mjpfhpj;Jf; fhzg;gLk;. 
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 T-Lymphocytes - ypUe;J Njhd;Wk; Neha; vjph;g;Gj; jpwDk; HLA-
DR4 mjpfhpj;Jf; fhzg;gLk;. 
 
3. Cd;: 
clypd; cUtj;ij mjd; njhopw;fpzq;f mikj;jYk; vd;ig 
tsHj;jYk; nra;tJ. 
khkprk; mNefkhf rpte;j epwKs;s rpW jirapiofs; jpuz;L 
clk;gpy; cs;s Ngrpfshk;.  Ngrpfspd; me;jq;fspy; (Ends of muscles) 
mjd; ,iofs; eirapy; (Tendons) Kbfpd;wd.  
cjpu thj RNuhzpjj;jpy; Cd; jhJ ghjpg;giltjhy; gpd;tUk; 
ghjpg;Gfs; Njhd;Wfpd;wd. 
- Tenosynovitis 
- Invasion of Collagen bundles 
- Partial or complete rupture of Tendons. 
 
4. nfhOg;G: 
xt;nthU cWg;Gk; jj;jk; nraiy ,aw;Wk; nghOJ fbdkpd;wp 
,aq;f> mtw;wpw;F nea;g;Gg; gir Cl;b cjtp GhptJ. 
,j;jhJ xt;nthU cly; mZf;fs; NjhWk; mitfspd; 
kj;jpkj;ijr; Rw;wp epiwa mike;Js;sd.  Njhypd; fPo; mlh;j;jpaha; 
mike;Js;sd. 
clYf;F rhptu czT+l;lg;glhj fhyj;jpy; Kd;G Nrkpf;fg;gl;l 
nfhOg;Gj; jhJ  czthf gad;gLfpwJ. 
nghUj;Jfs; fz;fs; Nghd;w cWg;Gfis jhf;fk;> mjph;Tfs; 
Nghd;wtw;wpypUe;J fhf;fpwJ. 
cjputhj RNuhzpjj;jpy;> There is loss of sufficient Lubrication 
that produces friction in between the bones of joints. 
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5. vYk;G: 
cliy xOq;Fgl epWj;jp itj;jy;> nkd;ikahd cWg;Gfisg; 
ghJfhj;jy;> cly; mirtpw;F mbg;gilahapUj;jy; Mfpa nray;fisr; 
nra;tJ. 
,sikapy; KUe;jhfTk; (Cartilage)> KJikapy; itukhfTk; 
(Hard) khWk; jhJ.  vd;Gfspd; re;jp Kfg;Gfspy; (Articular ends of 
bones) KUe;Jfs;(Articular Cartilages) fhzg;gLfpd;wd.  KUe;Jfspd; 
,rpTj;jd;ikahy; jhf;fj;ij Fiwj;J vYk;Gfs; ,yFtha; 
mirfpd;wd. 
cjpu thj RNuhzpjj;jpy;> Bone is eroded by Granulation tissue 
invasion and osteoclastic resorption.  Articular cartilage is eroded by 
proteolytic enzymes and directly invaded by pannus of granulation tissue. 
6. %is: 
vd;Gf;Fs; epiwe;J mitfSf;F td;ikAk; nkd;ikAk; jUtJ. 
7. Rf;fpyk; / RNuhzpjk;: 
jd;idnahj;j cUtg; ngUf;fpw;F ,lkhfpa fUj;Njhw;wj;jpw;F 
Kjyha; epw;gJ. 
 cjpu tsp RNuhzpjj;jpy; rhuk;> nre;ePh;> Cd;> nfhOg;G> vd;G 
Mfpa cly;jhJf;fs; Nkw;$wpathW ghjpg;gile;Js;sd. 
 
Kf;Fw;w NtWghL: 
 thjk; thOkplq;fspy; vd;Gk;> %l;LfSk; Kf;fpakhdit.  vdNt> 
mirTfSf;Fk;> elg;gjw;Fk;> XLtjw;Fk; fhuzkhfpd;wd. 
 cjputhj RNuhzpjj;jpy; thjk; ghjpf;fg;gl;L> mjdhy; guTfhy;> 
fPo;Nehf;Ff;fhy; ghjpf;fg;gLfpd;wd. 
o guTfhy; ghjpf;fg;gLtjhy; typ> tPf;fk;> %l;Lfis mirf;f 
rpukk; Vw;gLfpd;wd.  
o fPo;Nehf;Ff;fhy; ghjpf;fg;gLtjhy; kyr;rpf;fy; Njhd;WfpwJ.  
o Njtjj;jd; ghjpf;fg;gLtjhy; J}f;fkpd;ik Vw;gLfpwJ. 
o thjj;Jld; fgk; ghjpf;fg;gl;L %l;Lfis mirf;f rpukk; 
Vw;gLfpwJ. 
o gpd;dh; gpj;jk; ghjpf;fg;gl;L rhjfkhd gzpfis nra;a 
,ayhik Vw;gLfpwJ. 
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fhy epiyfspy; khw;wk;:     
 jd;dpiy tsh;r;rp Ntw;Wepiy tsh;r;rp
jd;ddpiy 
miljy; 
thjk; 
KJNtdpy; 
(Mdp> Mb) 
#d; 15 - 
MfRL 15 
fhh;fhyk; 
(Mtzp>Gul;lhrp) 
MfRL 15 - 
mf;Nlhgh; 15 
 
$jph;fhyk; 
(Ig;grp>fhh;j;jpif)
mf;Nlhgh; 15 - 
brk;gh; 15 
 
gpj;jk; 
fhh;fhyk; 
(Mtzp>Gul;lhrp)
MfRL 15 - 
mf;Nlhgh; 15 
 
$jph;fhyk; 
(Ig;grp>fhh;j;jpif) 
mf;Nlhgh; 15 - 
brk;gh; 15 
Kd;gdp 
(khh;fop> ij) 
brk;gh; 15 - 
gpg;uthp 15 
fgk; 
gpd;gdp 
(khrp> gq;Fdp) 
gpg;uthp 15 - 
Vg;uy; 15 
,sNtdpy; 
(rpj;jpiu> itfhrp)
Vg;uy; 15 - 
#d; 15 
KJNtdpy; 
(Mdp> Mb) 
#d; 15 - 
MfRL 15 
 
 
KJNtdpy; fhyj;jpy; #hpa ntg;gj;jpd; fhuzkhf ngUk; thhpahd ePh; 
Mtpahf;fg;gl;L cyfj;jpy; twl;rp Vw;gL;k;.  mJNghy; ekJ clypy; twl;rp 
Vw;gl;L tspNeha; tUtjw;F fhuzkhfpd;wJ. 
cjputhj RNuhzpjk; kUj;Jt Ma;tpy;> fhh;fhyk;> $jph;fhyk;> 
KJNtdpy; fhyk; ,tw;wpy; Nehahspfisf; fhz Kbe;jJ. 
KJNtdpy; fhyj;jpy; twl;rp fhuzkhf cjputhj RNuhzpj 
Nehapy; typ> tPf;fk; Nghd;w FwpFzq;fs; Njhd;wpd. 
  fhh;fhyj;jpy; kio nghoptjhYk;> $jph;fhyj;jpy; ePh;epiyfs; 
fyq;fp Rw;Wg;Gwk; Fsph;e;jpUg;gjhYk; Njhd;Wk; mjpfg;gbahd 
Fsph;r;rpahy; jhf;fg;gl;L cjputhj RNuhzpj Nehapy; %l;Lfspy; 
fhZk; jirg;gpbg;Gfs; (Stiffness) mjpfhpj;Jf; fhzg;gl;ld. 
cly; td;ik : 
 cly; td;ik %d;W tifg;gLk;. 
1. ,aw;if td;ik  -gpwtpapNyNa jUtpg;gJ. 
2. fhy td;ik  -tajpy; jUtpg;gJ. 
3. nraw;if td;ik  -czT kw;Wk; gof;ftof;fq;fshy; jUtpg;gJ. 
 cjpu thj RNuhzpjj;jpy; ,aw;if td;ik> nraw;if td;ik 
ghjpf;fg;gl;Ls;sJ. 
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Neha; epjhdk;: 
 
 ‘A+fp itj;jpa rpe;jhkzp” E}ypy; 80 thjq;fspy; %l;Lfspy; 
tUk; tpahjpfisg; gw;wp rpy thjq;fspy; $wg;gl;Ls;sJ. 
 
1. fhshQ;rf thjk; 
2. re;J thjk; 
3. ehpj;jiy thjk; 
4. kiyj;jfk;g thjk; 
5. igj;jpa thj RNuhzpjk; 
6. thj RNuhzpjk; 
 
fhshQ;rf thjk;: 
 
 “ thjkhq; fhy;ifapw; Fwq;fpuz;Lk;  
tFj;Jre;J KWf;fpNa File;J nehe;J  
ehjkh eiljhDe; jhd;nfh lhk  
dype;JNk Klkhfpf; fuL fl;br;  
NrjkhQ; rle;jhD kpfnt Sj;Jj;  
jpdNthL rpuq;Fkha;r; rpNyl;k khfpf;  
fhjkh aUrpnahL kaf;fkhFq;  
fUjpafh shQ;rfkhk; thjk khNk” 
 
¾ if>fhy;> njhil> %l;L mitfspy; gpsg;gJ Nghd;Wk;> 
FiltJ Nghd;Wk;> nehe;J> elf;fnthl;lhkw; nra;Ak;. 
¾ cly; nkype;jpUf;Fk;. 
¾ re;Jfs; NjhWk; Klq;fp> fuL fl;bf; nfhs;Sk;. 
¾ cly; kpf ntSj;Jj; jpdntLj;Jr; nrhwp rpuq;Fz;lhk;. 
¾ Iak; $b> Ritapd;ik> kaf;f Kjypad cz;lhFk;. 
re;Jthjk;: 
 
 “nra;ifjhd; re;JfS kpfj;jp kph;e;J 
  rlnkq;Fk; nehe;JNk kpft ow;wp  
eifaha; eSj;JNk kaph;f;Tr; rpl;L 
ez;zpNa Kd;Nghy elf;nfhl; lhJ  
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ikifjhd; kaf;fnkhL tha;eP &Wk;  
twz;bLNk ehTe;jhd; mbf;f bf;F 
ijifjhd; juzpjdpy; jhpf;nfh zhJ 
rrypf;FQ; re;Jfspd; tspf shNk”. 
 
¾ fPy;fs; NjhWk; epkph;e;J clnyq;Fk; nehe;J kpFe;j mow;rp 
cz;lhFk;. 
¾ kaph;f; $r;nrwpAk;. 
¾ elf;f Kbahik> kaf;fk;. 
¾ tha;eP&wy;> ehtwl;rp 
¾ fhy;fs; epyj;jpy; itf;f KbahjthW Jd;GWj;jy;. 
 
ehpj;jiy thjk;: 
 
 “ %h;f;fkha; Kad;W Koq; fhy;jhd; tPq;fp 
  Kjph;e;Juj;j Ke;jpuz;L Kaw;rpahfp 
 ePf;fkha; epd;wplnth zhkw; whDk; 
  epkph;e;jpLfpy; re;Je;jhd; Klf; nfhzhky;  
 jPh;f;fkha;j; Jz;bj;J kpfr; rpf;nfd;W  
  nrOikehpj; jiyNghy kpfNt tPq;fp 
 ehh;f;fkha; ehbANk glg lf;Fk; 
  ehpj;jiyapd; thjnkd;Nw etpy yhNk.” 
¾ Koq;fhy; %l;by; nre;ePh; epuk;gp> rpte;J> tPq;fpapUf;Fk;. 
¾ %l;bid ePl;lTk;> epw;fTk; Kbahky; ehpapd; jiyiag; 
Nghy;kpFjpAk; tPq;fpf; fhZk;;;. 
kiyj;jfk;g thjk;: 
 
 “Fk;gkhq; ifapd; kzpf;fl;L jd;dpw; 
  Ftpe;jiuapy; nkhj;ij NghYuj;Jf; fhZe; 
 Jk;gkh kq;fq;fs; Jbg;g jhFe;  
  Jz;LNk fhy;ifA eLf;f khFk; 
 mk;gkh kiuf;Fq;fPo; jpkpUz; lhFk; 
  mjuNk kpff;fWj;J ntbg;Gz; lhFk; 
 tk;gkhk; thAjhd; Ghpa ehw;wk; 
  tUkiyj;j fk;gj;jpd; khh;f;f khNk.” 
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¾ ifapd; kzpf;fl;Lg; G+l;Lfspy; tPq;fpj; jbj;Jf; fhZk;. 
¾ cly;; Jbf;Fk;> iffhy; eLq;Fk;. 
¾ miuf;Ff; fPo;j; jpkpUz;lhFk;. 
¾ cjL kpff; fUj;J ntbg;Gz;lhFk;. 
¾ kpf;f ehw;wj;Jld; fhw;Wg; ghpAk;. 
 
igj;jpathj RNuhzpjk;: 
 
 ‘ czh;r;rpahr; RNuhzpje;jhd; kpfnt Jk;gp 
  Cf;fkha;j; Njfnkq;F kpfNt nehe;J 
 Kzh;r;rpaha; Koq;fhy;fs; Koq;if nahf;f 
  Kidahd rpWtpuy; fd;dk; new;wp 
 jzh;r;rpaha;r; re;J rUthq;f nkq;Fe; 
  jhl;bf kha;f;File;J RuKKz;lhk; 
 gzh;r;rpaha;g; ghz;lJ Nghd; NkdpahFk;  
  gapj;jpa thj RNuhzpj;jpd; gz;G jhNd.” 
 
¾ Clypy; cs;s FUjp> gpj;jthjf; Fw;wg; ngUf;fhy; kpf;f 
nfhjpj;J. cly; KOikAk; gha;e;J> Nehfr; nra;Ak;. 
¾ Koq;fhy;> Koq;if> rpWtpuy;fs;> fd;dk;> new;wp 
Kjypaitfs; Nrhh;e;J> vy;yh cWg;GfSk; Nehfr; nra;Ak;. 
¾ Ruj;ijAk;> ghz;L> Nrhig NehiaAk;> gapj;jpaj;ijAk; 
gpwg;gpf;Fk;. 
 
thjRNuhzpjk;: 
 
‘mwpe;jpl;l tq;fnkyh nkypT khfp 
mirthd jt;tplq;fs; tPf;f khfp 
ewpe;jpl;l eilnfhlh jhdp Uj;jy;  
eypahfp nkhopnkhopa tPf;f khfr;  
nrhwpe;jpl;L Njfnkq;F kirT fhzy; 
Nrhw;wpd;Nk dpidtpd;wpj; J}f;f khjy; 
twpe;jpl;l thajdp dPh;jh D}wy; 
thjRNuh zpje;jhDk; tFj;j thNw”. 
27 
 
 
 
¾ cly; nkype;J miraf; $ba %l;Lfspy; tPf;fk; cz;L 
gz;Zk;. 
¾ elf;f Kbahky; gLf;ifapy; gLf;fr; nra;Ak;. 
¾ Neha; Kjpu Kjpu tPf;fk; kpFk;. 
¾ cly; eLf;fk;> cztpy; epidtpd;wp kpf;f J}f;fj;ij 
tUtpj;jy;. 
¾ thapy; ePh; Cwpf; nfhz;Nl ,Uj;jy; Mfpa FwpFzq;fs; 
thj RNuhzpjj;jpy; Njhd;Wk;. 
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Neha;; fzpg;G: 
  
Neha;fisf; fzpj;jwpAk; gpzpawp KiwikahdJ 
fPo;f;fz;l %d;W $Wfis cs;slf;fpaJ. 
1. nghwpahy; mwpjy; 
2. Gydhy; mwpjy; 
3. tpdhjy; 
nghwpahy; mwpjyhtJ nka;> tha;> fz;> %f;F> nrtp vDk; 
Ik;nghwpfspd; Jiznfhz;L mwpjyhFk;. 
Gydhy; mwpjyhtJ Ik;nghwpfspd; njhopy;fshd CW> Rit> 
ghHit> ehw;wk;> Xir vDk; Gyd;fspd; cjtp nfhz;L Nehiaf; 
fzpj;jwpjyhFk;. 
tpdhjyhtJ Nehapd; Njhw;wk;> guty;> jd;ik gw;wpa tptuq;fis 
NehahplNkh> mtuJ cjtpahshplNkh Nfl;L mwpe;J nfhs;SjyhFk;. 
,t;tifg; gpzpawp KiwikahdJ etPd kUj;Jtj;jpy; 
Nkw;nfhs;sg;gLk; Interrogation, Inspection, Palpation And Percussion 
Mfpatw;iw xj;Js;sJ. 
,itad;wpAk;> vz;tifj; NjHTfs; %yKk; Nehawpe;Js;sdH 
rpj;jHfs;. 
   ‘ehb ghprk; ehepwk; nkhop tpop 
kyk; %j;jpukpit kUj;Jt uhAjk;” 
- Njud;. 
vz; tifj; NjHTfs;: 
1. eh 
2. epwk; 
3. nkhop  
4. tpop 
5. kyk; 
6. %j;jpuk;  
7. CW 
8. ehb 
 
,e;j vz; tpj NjHTfSk; Kw;$wpa %tpj gpzpawp 
Kiwikapy; mlq;Fk;. 
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1. eh: 
 ghjpf;fg;gl;l Fw;wq;fSf;Fj; jf;fthwhd epwk; kw;Wk; Rit> 
khg;gbe;jpUj;jy;> Gz;> tPf;fk; Kjypatw;iw mwpjyhFk;. 
 cjputhjRNuhzpjj;jpy; ehtpy; khg;gbe;jpUj;jy; fhzg;gl;lJ. 
2. epwk;: 
 ghjpf;fg;gl;l %l;Lfspy; Neha; epiyf;Fj; jf;fthW rpte;jpUj;jy; 
fhZk;. 
3. nkhop: 
 Nehahsp NgRk;NghJ cuj;j xyp> rkxyp> Fuw;fk;kpa Ngr;R> 
jho;e;j xyp Kjypatw;iw mwpjyhFk;. 
4. tpop: 
 fz;fspd; epwk;> ePHtbjy;> tPq;fy;> fz;ghHitapd; epiyik> 
Gz;zhjy; Kjypatw;iw Muha;jyhFk;. 
 5. kyk;: 
• epwk; 
• ,sfy;/Fok;ghfpaJ 
• kzk; 
• Eiu 
• ,Wfy; 
• ,uj;jk;> rsp fye;jpUj;jy; 
cjputhj RNuhzpjj;jpy; kyr;rpf;fy; Vw;gl;L kyk; ,Wfy; 
fhzg;gl;lJ. 
6. %j;jpuk;: 
,Utifahd rpWePH ghpNrhjidfs; cs;sd. 
  1. ePHf;Fwp  2. nea;f;Fwp 
1. ePHf;Fwp: 
 ‘mUe;Jkhwp ujKk; mtpNuhjkjha; 
  m‡fy; myh;jy; mfhyT+z; jtph;e;jow; 
  Fw;wstUe;jp cwq;fp itfiw 
  Mbfyrj; jhtpNa fhJ nga; 
njhU K$h;j;jf; fiyf;Fl;gLePupd; 
 epwf;Fwp nea;f;Fwp epUkpj;jy; flNd” 
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 cz;Zfpd;w mWRitg; nghUs;fSk;; xd;Wf; nfhd;W 
Ntw;WikailahkYk;> grpf;Fj; jf;fgb Fiwj;jy;> mjpfhpj;jy;> 
fhye;jg;Gjy; Kjypa Fw;wq;fSz;lhfh tz;zk; Grpj;J cwq;fp> 
tpbaw;fhyj;jpy; gbf ghj;jpuj;jpy; ePiu Mtp Nghfhjgb nga;j 3¾ 
ehopiff;Fs; mjd; epwf;FwpiaAk>; mjpy; vz;nza; tpl;Lg; ghh;j;J 
fhzg;gLfpd;w FwpiaAk; ftdpj;J gpzpfspd; jPUk;> jPuhj Fwpfis 
nka;g;gpj;jy; KiwahFk;. 
‘te;j ePh; fhp vil kzk; Eiu vQ;rnyd; 
 iwe;jpaYsit aiwFJ KiwNa”  
    vd NjiuaH $wpagb> 
• epwk; 
• kzk; 
• vil 
• Eiu 
• vQ;ry; 
Mfpatw;iw Muha;jy; Ntz;Lk;. 
cjpu thj RNuhzpjj;jpy; ePh;f;FwpahdJ ,skQ;rs; epwj;jpy; 
fhzg;gl;lJ. 
 2. nea;f;Fwp: 
           ‘epwf;Fwpf;Fiuj;j epUkhz ePhpw; 
rpwf;fntz;nza;Nahh; rpWJsp eLtpLj; 
  njd;Wwj; jpwe;njhyp Nafh jike;jjp 
  dpd;wjptiyNghk; newptpop awpAk; 
  nrd;wJ GfYQ; nra;jpia AzNu”           
 - Njiuah;  
ePh; epwf;Fwpahy; Nehiaf; fz;L gpbj;jw; nghUl;Lr; nrhy;ypapUf;fpd;w 
tpjp nghUe;jpa rpWePhpy; xU rpwpa Jsp vz;nza;ia eLtpy; ifairtpdhy; 
vz;nza;j; Jsp rpjwhky; tpl;L nta;apyhdJ me;ePhpy; gLk;gb jpwe;J> 
fhw;whdJ mjpy; tPrp> me;j vz;nza;j; Jsp Mlhjgb itj;J> mr;rpWePhpy; 
tplg;gl;bUf;fpd;w vz;nza;j; JspahdJ nry;Yfpd;w topapy; 
fz;zwpitAk;> capuwpitAk; nrYj;jp> mj;Jsp njhptpf;Fk; Neha; 
tpsf;fj;ij  njhpe;J nfhs;sNtz;Lk;. 
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cjpu thj RNuhzpjj;jpy; nea;f;Fwp: 
 
 nea;f;Fwp Nehah;fspd; vz;zpf;if 
1 nkJthfg; guty; 4
2 ry;yilf;fz; 6
3 Kj;J Nghy; epw;wy; 5
4 xOq;fw;w tbtk; 5
 
cjpu thj RNuhzpjj;jpy; nea;f;FwpahdJ nkJthfg; guTtJk;> 
ry;yilf;fz; Nghy; guTtJk;> Kj;J xj;J epw;gJk;> xOq;fw;w 
tbtj;jpy; guTtJk; fhzg;gl;lJ. 
 
7. CW: 
ghjpf;fg;gl;l gFjpapy; iffshy; njhl;Lg;ghHj;J mwpjyhFk;. 
%l;Lfspy; ntg;gk;> njhLtyp czug;gLk;. 
 
8. ehb 
clypy; capH jhpj;jpUg;gjw;Ff; fhuzkhd rf;jp vJNth mJNt 
jhJ my;yJ ehb vdg;gLk;. 
 ngUtpuy; gf;fkhf kzpf;fl;Lf;F xU mq;Fyj;jpw;F Nky; Miu 
vd;gpd; NkNyhLk; ehb euk;G uj;jf; Fohapd; Nky; %d;W tpuy;fis 
tPiz kPl;LtJ Nghy; itj;Jr; rw;W mOj;jpAk; jsHj;jpAk; ghHf;f 
Ms;fhl;b tpuyhfpa Kjy; tpuypy; czHj;JtJ tsp vdTk;> eLtpuypy; 
czHj;JtJ moy; vdTk;> Rz;L tpuypy; czHj;JtJ Iak; vdTk; 
mwpayhk;.     
 
,lfiy +  mghdd; = tsp 
,lfiyAk;> mghdDk; $Ltjhy; tsp cz;lhfpwJ. 
gpq;fiy + gpuhzd; = moy;; 
gpq;fiyAk;> gpuhzDk; $Ltjhy; moy; cz;lhfpwJ. 
ROKid + rkhdd; = Iak; 
ROKidAk;> rkhdDk; $Ltjhy; Iak; cz;lhfpwJ. 
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cjputhj RNuhzpjj;jpy; ehbepiy: 
 
  ehb Nehah;fspd; vz;zpf;if
1. thj ehb 10
2. gpj;j ehb 5
3. thjgpj;j ehb 5
 
kUj;Jtk;: 
  
Kjy; ehs; kUj;Jtk;: 
 
 Kf;Fw;wj;ij rkg;gLj;j kUj;Jtk; Ghpjy; Ntz;Lk;.  
 
 ‘XJfpd;w kyf;fl;il nahopa itj;jhy;  
 clypYs;s thijnayh nkhLq;fpg; NghFk;” 
 
 ‘tpNurdj;jhy; thjk; jhOk;” 
 
 fopr;ry; cz;lhf;f Kjy; ehs; fhiy ntWk; tapw;wpy; nts;is 
vz;nza; 30 kp.yp. nfhLf;fg;gl;lJ. 
 Nghjpa msT fopr;ry; Vw;gl;l gpd;G> fopr;ry; epw;f NkhUk; md;iwa 
jpdk; czthf Nkhh; rhjKk; jug;gl;lJ. 
 
kWehs; kUj;Jtk;: 
 kWehs; Kjy; jpdKk;>  
cs; kUe;jhf Nkfehjp nkOF - 130 kp.fp. fhiy> khiy 2 
NtisAk; czTf;Fg; gpd;G gidnty;yj;Jld; jug;gl;lJ. 
ntspkUe;jhf Kf;$l;L vz;nza; typ> tPf;fKs;s %l;Lfspy; 
jlt jug;gl;lJ. 
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gj;jpak;: 
 
 ‘fLF ew;wpyj; njz;nza; $o;ghz;lq;fs; fliy 
 tLtjhfpa njq;Fkh tUf;if ew;fhak; 
kbtp yhj nts;Ss;spnfhs; Gifapiy kJngz; 
,lW ghfNyh lfj;jp ePf;fpypr; rhgj;jpak;” 
-rpj;jkUj;Jthq;fr; RUf;fk; 
‘cyfpypr;rhgj;jpaq; fz;^ h;$u khq;fha; 
ayfpdikf;fha; fj;jhpnfhj; jtiu - fyfKdp 
ke;jtif $\;khz;l khfLnfs; nsd;NwhU  
kpe;j tif ePj;Jz;gNj.”  
     - Njiuah; ijy th;f;fr; RUf;fk;. 
 
Nrh;f;ff; $lhj czTfs;: 
 
fLF – Brassica Juncea 
vs;nea; - Oil of Sesamuum indicum 
fy;ahz G+rzpf;fha; - Cucurbita pepo 
kJ – Alcohol varieties 
fliy – Cicer arietinum 
Njq;fha; - Cocos nucifera 
gyh – Artocorpus integrifolia 
khq;fha; - Mangifera indica 
fhak; - Ferula asafoetida 
nts;isg; G+z;L – Allium sativum 
nfhs;S – Dolichos bifious 
Gifapiy – Nicotiana tobaccum 
ghfy; - Momordica charantia 
mfj;jp –Sesbania grandiflora 
nfhj;jtiu – Cyamopsis tetrago 
ngz;Nghfk; -  Sexual intercourse 
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kUj;Jt mwpTiu: 
1. cztpy; Gspg;G> fhh;g;G> cg;G RitAs;s czTfis Fiwf;fTk;. 
2. Gujr; rj;Js;s czTfis mjpfkhf cl;nfhs;s Ntz;Lk;. 
(cjhuzk;: Kisfl;ba ghrpg;gaW) 
3. Rz;zr; rj;Js;s czTfis mjpfk; cl;nfhs;s Ntz;Lk;. 
(cjhuzk;: ghy;> gidnty;yk;) 
4. kyr;rpf;fy; ,y;yhyhky;; ,Uf;FkhW fPiu> fha;fwpfs;> goq;fs; 
mjpfkhf Nrh;f;f Ntz;Lk;. 
5. Fsph;fhw;W> gdpf;fhw;W> Fsph;e;j jiuapy; gLj;jy; ,tw;iw 
jtph;f;f Ntz;Lk;.  
6. nte;ePhpNyNa Fspf;f Ntz;Lk;. 
7. Nehapd; jd;ikfs; gw;wpa fUj;Jf;fis Nehah; kl;Lkpd;wp> 
mtUila FLk;gj;jpdh; midtUk; Ghpe;J nfhs;tjhy; 
,zf;fkhd> mikjpahd #o;epiyia jf;f itf;f KbAk;. 
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rpwg;G kUj;Jtk; 
njhf;fzk;: (kh;j;jdk;) 
 
 njhf;fzj;ij ‘kh;j;jdk;” vd;Wk;; $wyhk;.  ,J thjj;jhy; 
cz;lhFk; vy;yh Neha;fisAk; ePf;Ftjpy; rpwg;GilaJ. 
 
tiffs;: 
 njhf;fzk; nra;Kiw xd;gJ tifg;gLk;. 
1. jl;ly;  
2. ,Wf;fy; 
3. gpbj;jy; 
4. KWf;fy;  
5. fl;ly;  
6. mOj;jy; 
7. ,Oj;jy; 
8. ky;yhj;Jjy;  
9. mirj;jy; 
 
ehl;gl;l ghhprthjk;> Klf;Fthjk; ,itfs; kUe;jhy;  ePq;FtJ 
mhpjhdhYk;> njhf;fzj;jhy; ePq;Ftijf; fhzyhk;. 
 
 cjputhj RNuhzpjj;jpy;> 
 Nehapd; jPtpu epiyapy; njhf;fzk; nra;tJ jtph;f;fg;gLfpwJ. 
KO Xa;T kl;Lk; mwpTWj;jg;gLfpwJ.   
Nehapd; jPtpuk; Fiwe;j epiyapy; gpbj;jy; Kiwapy; kpf ,Nyrhf 
njhf;fzk; nra;a ed;ik gaf;Fk;. 
 
 ‘gpbj;j ypaq;F kikjp apDe;jUk;gpe;jjNj - vz;nza;  
 ALj;jJ nra;apw; wrtsp A+Dl Ye;jhNj” 
       - Njiuah; jU. 
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xw;wlk;: 
 thj Neha;fspy; xw;wlk; kpf;f ed;ik GhpfpwJ.   
 jOjhio (thjklf;fp)> thjehuhazd;> nehr;rp> Mkzf;F> gpukp> 
MlhNjhil Nghd;w %ypiffspy; VNjDk; xd;wpd;  ,iyfis rpWf 
mhpe;J vz;nzapy; tjf;fp Jzpapy; Kbe;J> ghjpf;fg;gl;l %l;Lfspy; 
xw;wlkplyhk;. 
 cjpu thj RNuhzpjj;jpy;> jOjhio ,iyfisf; nfhz;L 
nra;Ak; xw;wlk; ey;y gyid mspj;jJ. 
cjpu thj RNuhzpjj;jpy; vYkpr;rk; go xw;wlk; kpf;f ed;ik 
gaf;fpwJ. 
Mjhuk;:  ‘vYkpr;rk; goj;ij ,uz;lhf mhpe;J Jzpj;Jz;by; Kbe;J 
vz;nzapy; Njha;j;J xw;wlkplyhk;” 
      - rpj;jh; mWit kUj;Jtk; 
nra;Kiw: 
 vYkpr;rk; goj;ij ,uz;lhf mhpe;J> xU ghjpapd; tise;j 
Nkw;Njhy; gFjpapy; E}ypdhy; Nfhh;j;J> Kbr;rpl;Lf; nfhz;L> 
ntl;Lgl;l goj;jpd; gug;ig nghWf;Fk; msT #lhd ey;nyz;nzapy; 
Njha;j;J vLj;J> typ> tPf;fk; cs;s %l;Lfspy; xw;wlkplg;gl;lJ.  
goj;jpd; #L Mwpa cld; kPz;Lk; kPz;Lk; vz;nzapy; Njha;j;J  
vLj;J vy;yh rpwpa kw;Wk; nghpa %l;LfspYk; xw;wlkplg; gl;lJ.  
gad;: 
¾ The external heat produced by the Otradam (xw;wlk;) increases 
the vascularity around the affected joints and facilitates the 
venous return and lymphatic drianage. 
¾ Reduces the swelling of joints. 
¾ Reduces the inflammation. 
¾ Produces the flexibility of muscles around the joints. 
¾ Reduces the stiffness of joints. 
¾ It facilitates the range of movements of the affected joints 
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Nahfhrdq;fs;: 
 Nahfk; vd;gJ xUq;fpizg;G vd nghUs;gLk;.  Nahfhrdq;fs; 
cly; kw;Wk; kdij xUq;fpizf;Fk; gapw;rpfspy; Kf;fpakhdJ. 
 Mrdq;fs; ml;lhq;f Nahfj;jpy; %d;whtJ gbepiyahFk;. 
 ,jd; %yk; cly; cs; kw;Wk; ntsp cWg;Gfspd; typikAk;> 
nray;jpwDk; mjpfhpf;fpd;wd.  ehskpy;yh Rug;gpfs; 
rPuhf;fg;gLfpd;wd. 
 cjputhj RNuhzpjj;jpy; nghJthf fbdkhd Mrdq;fs; gapw;rp 
nra;tij jtph;j;jy; ey;yJ. 
 Nehapd; jPtpu epiyapy; rhe;jp Mrdk; nra;a ey;y gyd; 
fpilf;Fk;.  clYk; kdKk; Gj;Jzh;T ngWk;. 
 
rhe;jp Mrdk; (rthrdk;)  - nra;;Kiw : 
Rj;jkhd ,lj;jpy; tphpg;gpd; kPJ ky;yhe;J gLj;Jf; nfhz;L 
fhy;fs; ,uz;ilAk; rw;W ,ilntspAld; jsh;thf itj;Jf; 
nfhs;sTk;. iffis gf;fthl;by; ePl;b> cly; KotJk; kpf jsh;thf 
glj;jpy; fhl;bagb mikf;fTk;.   fz;fis ,Nyrhf %bf; nfhs;sTk;.  
Rthrk; rPuhf ,Uf;fl;Lk;. 
cly; ghfj;jpy; fhy; tpuy;fs; Kjy; fZf;fhy;fs;> Koq;fhy;> 
njhilfs;> ,Lg;G> tapW> khh;G> iffs;> fOj;J> Kfk; ,itfis 
thpirahf epidj;J Xa;T nfhLf;f Ntz;Lk;. Rthrk; rPuhf ,Uf;f 
Ntz;Lk;. ,e;epiyapy; rydkpd;wp 3 Kjy; 5 epkplk; ,Ue;J 
vOe;jpUf;fTk;. 
gad;: 
o cjpu thj RNuhzpjj;jpy; Vw;gl;l kdrQ;ryk; ePq;Fk;.  
o cly; fisg;ig Nghf;Fk;.  
o jirfs; Gj;Jzh;T ngWk;. 
o kNdhrf;jp tsUk;. 
o kdk; xUikg;gLj;jg;gLk;. 
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gpuhzhahkk;: 
 gpuhzhahkk; vd;gjd; nghUs; ‘%r;rlf;fy;’ vd;gjhFk;. %f;fpd; 
Jis topNa ,aq;Fk; fhw;iw jd; topg;gLj;Jtjd; %yk; clypd; 
nray;ghLfis rkepiyapy; itf;fyhk;. vg;gbnadpy;> %f;fpd; ,lJ Jis 
topahf gpuhzthA nry;tJ ,lfiy (re;jpu ehb) vdTk;> tyJ %f;Fj; 
Jis topahfr; nry;Yk; gpuhzthA gpq;fiy (#hpaehb) vdTk; 
miof;fg;gLfpwJ.  caphpdq;fspd; tho;Tf;F Mjhukhf cs;s xU epfo;T 
jl;gk;> ntg;gk; vd;w ,aw;ifr; rk epiyahFk;. 
,lJ ehrp topahf gpuhzthA nry;Yk; NghJ jl;gKk; tyJ ehrp 
topahf gpuhzthA nry;Yk; NghJ ntg;gKk; clypy; Vw;gLfpd;wd. 
Rthrj;jpd; ,e;epfo;Tfshy; clypd; ntg;gepiy rPuhf itf;fg;gLfpd;wJ. 
Neha;fspy; ,Ue;J cly; fhf;fg;gLfpd;wJ.  
kUj;Jtg; gad;fs;: 
• gpuhzhahkj;jpdhy; ru Xl;lk; rPuhf;fg;gl;L mjd; %yk; tsp> 
moy;> Iak; Mfpa %d;W capHj;jhJf;fSk; rkepiyapy; elf;Fk;.  
%d;W caph;jhJf;fSk; rPuilAk; NghJ Neha;fSk; fl;Lg;gLk;.  
cjputhj RNuhzpjj;jpy; ghjpg;gile;j tsp> moy; 
rkg;gLj;jg;gLfpwJ. 
• clypd; jl;g ntg;gk;  rkepiyapy; itf;fg;gLfpd;wJ.  
• cly; jpRf;fSf;F mjpfsT capHfhy; fpilf;fpd;wJ. 
• Rthrj;jpw;Fk;> kdjpw;Fk; neUq;fpanjhlh;G ,Ug;gjhy; cjputhj 
RNuhzpjj;jpy; Njhd;Wk; kdrypg;G (Depression) ePq;fp> 
kdtypikAk; (Self confidence)> ey;y J}f;fKk;(Quite sleep) 
cz;lhfpwJ. 
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jpahdk;: 
 
 gpuj;jpahfhuk; %yk; Gyd; xLf;fk; nra;J> jhuiz%yk; kdij 
xUKfg;gLj;jp> jpahdk; %yk; xUKfg;gLj;jp Ftpf;fg;gl;l 
vz;zj;jpNyNa ,iltplhJ njhlh;e;J epiyj;jpUf;f gapw;rp 
fpilf;fpwJ. 
 %yhjhuk;> Rthjpl;lhdk;> kzpg;G+ufk;> mdhfjk;> tpRj;jp> 
Mf;fpid vd;Dk; MW Mjhuq;fSk; clypYs;s ehskpy;yhr; 
Rug;gpfSld; ,izahf mike;Js;sd. ,it cly; Mw;wy; 
ikaq;fshf mike;Js;sd.  ,it rk epiyapy; ,Uf;Fk; NghJ 
clypy; gpzpapy;iy.  ,jd; rkepiy jtWk; gl;rj;jpy; mjdjDf;F 
jf;fthW cly; cghijfs; Njhd;Wk;. 
jpahdk; %yk; Mjhuq;fs; rPh;gl;L Neha; ePf;fj;jpw;F kl;Lkpd;wp 
Neha; tuhkYk; jLf;fyhk;. 
 cjputhj RNuhzpjj;jpy; ngUk;ghyhd Nehahspfs; tUj;jk;> 
rypg;Gld; fhzg;gLfpd;wdh;. 
,th;fSf;F jpahdg;gapw;rp %yk; ek;gpf;ifAk; (confidence);> 
Gj;Jzh;r;rpAk;(Refreshment) fpilf;fpd;wd. 
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RHEUMATOID ARTHRITIS 
 
 The term ‘Rheumatoid’ has been derived from the Greek words 
‘Rheuma’ and ‘Eidos’.  It was first proposed by Sir Alfred Barring Garrod 
in 1858. 
RHEUMATOID – RHEUMA + EIDOS 
 RHEUMA – Flux ;  Flux – To flow out 
 EIDOS -  Resemblance ;  
 RHEUMATOID – Resembling Rheumatic Arthritis in one or more 
features. 
 
DEFINITION: 
 A generalized disease, occurring more often in women, which 
primarily affects connective tissue; Arthritis is the dominant clinical 
manifestation involving  many joints, especially those of the hands and 
feet, accompanied by thickening of articular soft tissue, with extension of 
synovial tissue over articular cartilages which become eroded; The course 
is variable but often is chronic and progressive leading to deformities and 
disability. 
Rheumatoid Arthritis: 
 Rheumatoid Arthritis is the commonest cause of chronic 
inflammatory joint disease.   
 The most typical clinical features are, 
o Symmetrical Poly Arthritis 
o Teno synovitis 
o Morning Stiffness 
o Elevation of ESR 
o Appearance of Anti Ig G Globulins or Rheumatoid Factor in 
the serum. 
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In Rheumatoid Arthritis changes can be widespread in the tissues 
of the body and the condition should really be called “Rheumatoid 
Disease”. 
 
Incidence:  
 The prevalence of the disease  is Rheumatoid Arthritis  is 1 to 3 % 
and the peak incidence  is in the 4th or 5th decades.  Out of them women 
are affected 3 or 4 times as commonly as men. 
 Prevalence and clinical expressions vary between populations;  
More common and generally more severe in Urban communities of 
Europe and North America than in the rural populations of Africa. 
 
CAUSES :  
 The cause of Rheumatoid Arthritis  is still incompletely worked 
out.  A great deal is now known about the circumstances in which it 
develops and Hypothesis about its Etiology and Pathogenesis have been 
narrowed down to manageable lines of discussion. 
 
Evolution of RA: 
 The most important factors in the evolution of RA are, 
1. Genetic Susceptibility 
2. Immunological Reaction possibly involving a foreign Antigen, 
preferentially focused on Synovial tissue. 
3. An Inflammatory Reaction in Joints and Tendon Sheaths. 
4. Appearance of Anti IgG Antibodies in the Blood and 
Synovium. 
5. Perputation of Inflammatory process 
6. Articular Cartilage Destruction. 
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1. GENETIC SUSCEPTIBILITY: 
     Rheumatoid Arthritis is more common in first degree relatives of 
patients than in the population at large.  Further more twin studies 
have revealed a concordance rate of around 30% if one of the pair is 
affected. 
 
2. IMMUNOLOGICAL REACTION: 
The Human Leucocyte Antigen – HLA DR4 occurs in about 70% 
of people with  Rheumatoid Arthritis  compared to a frequency of less 
than 30% in normal controls. 
HLA DR4  is encoded in the Major Histo Compatibility Complex 
(MHC) region on chromosome 6. 
 In common with other HLA class II molecules, it appears as 
surface antigen on cells of the Immune system – B Lymphocytes, 
Macrophages, Dendritic Cells, which can act as Antigen Presenting 
Cells - APCs. 
 In some, T-cell immune reactions, the process is initiated only 
when the Antigenic Peptide is presented in association with a specific 
HLA allele. 
 It  has been suggested that this is the case in people who develop 
Rheumatoid arthritis;  The idea is even more attractive if one posits 
that the putative antigen has a special affinity for synovial tissue. 
 
3. INFLAMMATORY REACTION: 
Once APC/ T-Cell interaction is initiated, various local factors 
come into play, and lead to a progressive enhancement of the immune 
response. 
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 Marked proliferation of cells in synovium with appearance of 
Cytokines, which are important in mediating intercellular 
communications and activating  macrophages and B-cells. 
 Local factors also have a role in stimulating vascular proliferation, 
resulting in Synovitis both in joints and Tendon sheath linings Hall 
mark of early Rheumatoid arthritis. 
 
 
INFLAMMATORY REACTION 
 
APC / T-Cell interaction initiated 
 
Local factors plays 
 
Immune Response Enhancement 
 
Marked proliferation of cells in synovium 
 
Appearance of cytokines 
(For intercellular communication and 
Activation of Macrophages and B-Cells) 
 
Local factors activated 
 
Vascular proliferation 
 
                                            Synovitis 
 
Hall mark of early RA 
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4. RHEUMATOID FACTOR: 
Followed by the B-Cell activation production of Anti IgG Auto 
antibodies are detected in blood as RHEUMATOID FACTOR (RF). 
Rheumatoid Factor – Antiglobulins play an important role in 
perpetuating the chronic inflammatory process.  
 
5. CHRONIC SYNOVITIS: 
Associated with proteolytic enzymes, Tissue factors 
(Prostaglandins), interleukin-I(IL-1), Anti-collagen antibodies – 
Immune  complexes are deposited in the synovium and articular 
cartilage, where they appear to augment the inflammatory process.  
 
6. JOINT DESTRUCTION:  
Combination of  factors  lead to  
o Depletion of the cartilage matrix  
o Damage to chondrocytes 
o Vascular proliferation 
o Osteoclastic activity (most marked at the edges of 
Articular surface) 
o Cartilage destruction 
o Periarticular bone erosion. 
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PATHOLOGY 
Pathololgy of  Rheumatoid Arthritis is divided in two major parts. 
 
I. Pathology of Joints and Tendons 
II. Pathology of Extra articular tissues. 
 
I. PATHOLOGY OF JOINTS AND TENDONS 
It can be explained in three stages. 
1. Synovitis. 
2. Destruction 
3. Deformity 
1. Synovitis: 
In this stage the following early changes are seen: 
o Vascular congestion 
o Proliferation of synoviocytes 
o Infiltration of synovial layers by polymorphs, 
lymphocytes, plasma cells. 
o Thickening of capsular structure 
o Villous formation of synovium 
o Cell-rich effusion into joints and tendon sheaths 
Though this stage was painful, swollen and tender, their structures are 
still intact and mobile.  So, these disorders are reversible potentially. 
2. Destruction: 
Articular cartilage: 
Articular cartilage is eroded partly by proteolytic enzymes and 
partly by vascular tissue in folds of synovial reflection. 
Direct invasion of cartilage by pannus of granulation tissue 
creeping over articular surfaces. 
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Margins of joints: 
 Bone is eroded by granulation tissue invasion and osteoclastic 
resorption. 
 In recent thoughts there is Synovial Hyperplasia rather than 
inflammation. 
 
Tendons: 
 Tenosynovitis 
 Invasion of collagen bundles 
 Partial or complete rupture of tendons. 
Other changes: 
 Synovial effusion – contains copious amount of fibrinoid materials 
that produces swelling of joint, tendons and bursae. 
 
2. Deformity: 
In this stage , 
= Combination of  
 Articular destruction  
 Capsular stretching 
 Tendon rupture 
= produces Instability and then Deformity.  
 By this time, 
 Inflammatory process may have subsided 
The emphasis may be on the mechanical and functional effects of joint 
and tendon disruption. 
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PATHOGENESIS 
       Principal target site 
                                        
       Synovium, vasculitis 
                                 (increased vascularity,odema) 
                                  congestion, villous hypertrophy 
 
               Fibrinoid degeneration necrosis 
                          
Inflammatory cell infiltration 
                  (Lymphocytes, monocytes, macrophages,plasma cells) 
                                           
       Fibroblastic proliferation 
                      (Palasaded histiocytes) 
 
                                             Rheumatoid granulation 
                  (“Pannus” invading connective tissue by creeping substitution) 
 
 
Capsule and     Tendon and       Joints/Articular             Subcutaneous 
ligaments        aponeuroses      cartilage       tissues/bursae       
                                                                
Edema    Tendon synovial        Deprivation of      Nodules     Bursitis 
   sheath infiltration           nutrition           (Aschoff’s) 
Laxity Fibrosis      
        Pannus invasion   Cellular death 
  Of adjacent tendons  Fragmentation of articular 
 
Subluxation  Contractures  
 
Dislocations Severe    Avascularity and attrition           Total destruction of cartilage 
     Deformities 
  Attenuation and rupture                         Ankylosis  
           Disorganization of joint 
                   Secondary deformity 
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PATHOGENESIS: 
 There is a genetic predisposition of RA and that the joint 
inflammation is immunologically mediated; however, the initating agent 
and the precise interplay between genetic and environmental factors 
remain to be clarified. 
 In all likelihood the disease is initiated by activation of helper T 
cells responding to some arthritogenic agent (MICROBE).  Activated 
CD4+ cells produce a number of cytokines that have two principle 
effects:  
(1) Activation of macrophages and other cells in the joint space, 
which release tissue destructive enzymes and other factors that perpetuate 
inflammation. 
(2) Activation of the B-cell system, resulting in the production of 
anti-bodies, some reactions damage the joints and are believed to play an 
important role in disease progression.  
In the context of this general scheme the role of genetic factors, T -
cells, cytokines, B cells, and infectious agents are participated. 
 
IMMUNOGENESIS: 
 The role of immune processes in the development of the 
rheumatoid lesions is indicated by a number of observations of patients 
with the disease: 
1. The presence of gamma globulins (in particular, IgG and IgM) in 
synovial fluid and leukocytes, in synovial plasma cells, lymphoid 
centers, and lining cells and in subcutaneous nodules and vessel 
walls. These gamma globulins are not a direct cause of rheumatoid 
disease, since the disease occurs in persons with 
Agammaglobulinemia. 
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2. The presence of RF in synovial plasma cells and in syovial lining 
cells, which are capable of synthesizing RF. 
3. The presence of synovial leukocytes, interstitial connective tissue, 
and lining cells of complement components associated with 
decreased complement titers in the synovial fluid. 
5. The presence of IgG, IgM and B1c complement in the articular 
cartilage of patients with first or second degree Osteoarthrosis. 
6. The presence of antinuclear factor (ANF) in the serum of patients 
with advanced disease; this suggests a role of autoimmunity, if not 
as the primary cause then perhaps owing to the chronicity of 
rheumatoid arthritis. 
7. The common association of rheumatoid arthritis with amyloidosis. 
 
HISTOGENESIS: 
On the basis of available histologic and immumologic data, a 
concept of the histogenesis of rheumatoid arthritis has evolved. 
 An antigen, which could be extraneous (related to infection) or 
endogenous (related to abnormal gamma globulins), gains access to the 
joint cavity and elicit an immune reaction that is both humoral and cell 
mediated and in which polymorpho-nuclear leukocytes, T and B 
lymphocytes, and macrophages interact. 
 Complexes of various immunoglobulins, RF, and complement -
some quite large and insoluble are formed and phagocytosed by cells 
termed RA cells or phagocytes.  Thus the inflammatory process is set in 
motion, terminating in the formation of granulation tissue and scarring.  
Lysosomal enzymes from the cells of the exudates and from the pannus 
participate in the destruction of cartilaginous matrix by degrading both 
proteoglycans and collagen.  They thus play a major role in the 
deterioration of the joint. 
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II. PATHOLOGY OF EXTRA ARTICULAR TISSUES. 
1. Rheumatoid nodule  
2. lymphadenopathy, splenomegaly 
3. vasculitis 
4. muscle weakness 
5. visceral diseases 
Rheumatoid  nodule  
Rheumatoid nodule is a small granulomatous lesion consisting of 
central necrotic zone, surrounded by a radially disposed palisade of local 
histiocytes and beyond that by inflammatory granulation tissue. 
Nodule occurs 
 Under the skin especially over subcutaneous of bony 
prominenece 
 In the synovium 
 On the tendons 
 In the sclera 
 In many of the viscera. 
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ONSET OF RHEUMATOID ARTHRITIS: 
• Usually insidious with symptoms emerging overa period of months 
• Occasionally the disease starts quite suddenly. 
• Some factors may be involved in the initiation of the process.  
 
They are, 
1.Infectious Agents: 
Isoloation of variety of organisms from the synovial tissue, 
synovial fluid blood of the affected persons, supports this possibility. It 
includes Diphtheroid bacilli, Mycoplasma, Viruses especially Ebstein 
Barr Virus 
 
2.Trauma: 
 Traumatic incidence is a precipitating cause for the development of 
Rheumatoid Arthritis. 
 
3.Psycological  Stress: 
It also plays a role. 
 
4.Vascular changes: 
 Alteration of peripheral vascular bed with autonomic influence 
which causes the symmetrical pattern of arthritis. 
 
5.Neurogenic factor: 
Neuropeptide can cause inflammation. These peptides which are 
from sympathetic fibers of spinal cord are responsible for the 
inflammation. This is confirmed by the incidence of severity of R.A. in 
the nonparalysed side of the hemeplegic patients. 
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CLINICAL FEATURES OF RHEUMATOID ARTHRITIS 
 
Clinical Features of RA are dealt with two stages.  
I. Early stage  
II. Later stage 
EARLY STAGE: 
 Mainly, 
1. poly synovitis 
2. soft tissue swelling 
3. stiffness 
Complaints: 
¾ Pain, swelling loss of mobility in Proximal Inter Phalangeal (PIP) 
Joints of fingers. 
¾ Then time passes, spreading of symptoms to other joints that are, 
wrist, feet, knees, shoulders in order of frequency. 
¾ Stiffness – generlalised stiffness after a period of inactivity and 
after rising from bed in early morning. 
Physical signs: 
Inspection: 
 Slight but usually symmetrical swelling in Metacarpo-phalangeal 
joints (MPJs), Proximal Inter Phalangeal Joints and Wrists. 
Palpation: 
 Local warmth in larger joints 
 Tenderness  
 Thickening 
 Crepitation on passive movements 
 Teno synovitis common in extensors of wrist and flexors of 
fingers. 
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Movements: 
 In early stage, Movements of joints are limited and restricted. 
 But joints are still stable.  Deformities are unusual. 
LATER STAGE: 
 
Complaints: 
¾ Acute pain (of synovitis) leading to more constant ache(of 
progressive joint destruction) 
¾ Functions are increasingly disturbed. 
¾ Needs help in dressing and eating. 
 
Inpection: 
Rheumatoid deformities due to combination of joint instability and 
tendon rupture. 
Ulnar deviation of the fingers 
Radial and volar displacement of wrists 
Valgus knees 
Valgus feet 
Clawed toes 
 
Movements: 
 In the later stage of RA, there is Restricted and Painful movements. 
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INVOLVEMENTS  OF INDIVIDUAL JOINTS 
Hands and wrist: 
  Rheumatoid arthritis often causes symmetric arthritis with 
characteristic involvement of certain specific joints such as proximal 
interphalangeal joints and metacarpo-phalangeal joints.  The distal inter-
phalangeal joints are rarely involved. 
 In early course of the disease, there may be spindling of the 
progress due to synovial hypertrophy and effusion in the interphalangeal 
joints.    Later, marked synovial hypertrophy on the dorsum of the wrist 
with involvement of extensor tendon sheath results in dropped finger.  
The same process in the palmar aspect may lead to carpal tunnel 
syndrome. 
 Persisting synovitis, weakening of the capsule, muscle wasting, 
tendon rupture and destruction of the articular surface leads to 
characteristic Rheumatoid hand deformity, which includes: 
a. “Swan neck deformity” with hyperextension of the proximal 
interphalangeal joints with fixed flexion of the distal 
interphalangeal joints. 
b. “Button hole deformity” (Boutoniere deformity) which includes 
fixed flexion of the proximal interphalangeal joints and 
extension of the distal interphalangeal joints. 
c. “Z deformity” of the thumb (Radial deviation at the wrist with 
ulnar deviation of the digits often with palmar subluxation of 
the proximal interphalangeal joints). 
d. Hyper extension of the first interphalangeal joints and flexion of 
the first metacarpophalangeal joint with consequent loss of 
thumb mobility and pinch. 
Palmar erythema is also common.   
Raynaud’s phenomenon may occur in the early stage. 
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Feet and Ankles: 
 Active synovitis in the metatarsophalangeal joint can produce pain 
and tenderness best elicited by the lateral squeezing of the joints. 
 The synovial swelling of the active disease together with 
destruction of the ligament between the metatarsal heads may broaden the 
forefoot and separate the toes to produce the “day light sign”. 
 Deformities may also develop in the feet including eversion at the 
hind foot (subtalar joint), plantar subluxation of the metatarsal heads, 
widening of the forefoot, hallux-valgus and lateral deviation and dorsal 
subluxation of the toes.  So the patient walks on the unprotected heads of 
the metatarsal bones.  The patient complains of a feeling of walking on 
pebbles and the metatarsal heads are readily palpable on the sole of the 
foot. 
In the hind foot calcaneal erosions, hallux-valgus deformities are 
found. 
 Rheumatoid synovitis may develop in the subtalar and midtarsal 
joints.  Chronic arthritis in this region can lead to “pesplano-valgus 
deformity”. 
 
Knee Joints: 
 Knee joint is commonly involved with synovial hypertrophy, 
chronic effusion, and frequently ligmentous laxity.  Pain and swelling 
behind the knee may be caused by extension of inflammed into the 
popliteal space (Baker’s cyst). 
 Wasting of quadriceps is present, Flexion contractures may 
develop. 
 Both cruciate and lateral ligaments may be destroyed, resulting in 
gross joint instability and valgus deformity or varus deformity. 
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Elbow and Shoulder Joints: 
 Inflammed olecranon bursae and Rheumatoid nodules around the 
elbow are common but true rheumatoid arthritis affecting the elbows is 
less common.  Severe destructive changes can occur leading to “fixed 
flexion deformity”. 
 Pain in the shoulder can be referred from the neck or be due to 
involvement of acromio-clavicular joint, sub-acromial bursa, rotator cuff 
and bicipital tendon as well as the gleno-humeral joint. 
 
Cervical Spine: 
 The upper cervical discs are frequently involved.  The cervical 
vertebrae may become subluxed and this may cause serious neurological 
disorders. 
 The atlantoaxial articulations and their associated ligaments are 
frequently involved.  Separation between the odontoid process and the 
first cervical vertebra exceeds the normal of 2 to 3 mm that can be 
detected by X-ray.  They complain pain in the cervical spine that radiates 
upwards over the occiput, and vertex to the forehead. 
 Atlantoaxial dislocation may cause the vertebrobasilar 
insufficiency or may produce neurological signs by direct pressure on the 
cord. 
 
Hip Joints: 
 The hip is less commonly involved but when it occurs, it causes 
serious disability.  Occasionally the disease remains monoarticular for 
several years but eventually other sites are affected.  Persistent synovitis 
in a weight-bearing joint soon leads to the destruction of the cartilage and 
bone.  The acetabulam is eroded and eventually the femoral head may get 
perforated at its floor.  The hallmark of the disease is progressive bone 
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destruction on both sides of the joints without any reactive osteophyte 
formation.  This is often referred to as “aseptic necrosis” and is more 
common in corticosteroid treated patients. 
 
Other joints: 
Rheumatoid arthritis affects all the synovial joints.  Temporo 
mandibular involvement produces pain on chewing.  Acromio clavicular,  
sterno clavicular and cricoartenoid joints may also be involved. 
 
Foot Deformities In Rheumatoid Arthritis 
• Callosity under PIP joint 
• plantar callosity 
• Atrophy of plantar metatarsal fat pad 
• Prominent metastarsel head 
• excessive plantar tilt of metarsals 
• claw toes  
• hammer toes 
• rheumatoid nodules 
• calcaneal erosions 
• achilles tendinitis 
• Flattening of longitudinal arch. 
• bunion 
• hallux valgus 
• overriding of second and third toes 
• splaying of forefoot due to divergent metarsals. 
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EXTRA – ARTICULAR MANIFESTATIONS 
 
Systemic: 
• Fever 
• Weight loss 
• Fatigue 
• Susceptibility of infection 
Vasculitis: 
• Digital arteritis 
• Ulcers 
• Pyoderma gangreosum 
• Mononeuritis multiplex 
• Visceral arteritis 
 
Musculoskeletel: 
• Muscle Wasting 
• Tenosynovitis 
• Bursitis 
• Osteoporosis 
Cardiac: 
• Pericarditis 
• Myocarditis 
• Endocarditis 
• Conduction defects 
• Coronary vasculitis 
• Granaulomatous aortitis 
Haematological: 
• Anaemia 
• Thrombocytosis 
• Eosinophilia 
Nodules: 
• Sinuses 
• Fistula 
 
Lymphatic: 
• Spleenomegaly 
• Felty’s syndrome 
Pulmonary: 
• Nodules 
• pleural effusion 
• Fibrosing alveolitis 
• Bronchiolitis 
• Caplan’s syndrome 
Occular: 
• Episcleritis 
• Scleritis 
• Scleromalacia 
• Kerato conjunctivitis sicca 
. 
Neurological: 
• Cervical Cord compression 
• Compression neuropathies 
• Peripheral neuropathy 
• Mononeuritis multiplex 
• Amyloidosis 
  
 
 
59 
 
 
INVESTIGATIONS: 
A.Haematological: 
1. ESR – Increased in active stage 
2. Serum proteins – Hyperglobulinaemia with elevation of 
Gamma and Alpha 2 globulins hypoalbuminaemia  during acute phase 
and C-reactive protein (CRP) 
B. Immunological: 
i. Rheumatoid Factor (RF): 
Latex screening positive 
  Latex test positive 
Sheep cell Agglutination Test (Roose Waaler) (SCAT) 
Differential Agglutination Test (DAT) 
Human Erythrocyte Agglutination Test (HEAT) 
Rheumatoid Factor (RF) is an auto antibody (Antibody directed 
against an organism’s own tissues).  It is an antibody against the Fc 
portion of IgG, which is itself an antibody.   
Rheumatoid Factor (RF)  is evaluated in patients suspected of 
having any form of arthritis even though positive results can be due to 
other causes, and negative results do not rule out disease.  But, in 
combination with signs and symptoms.  
Rheumatoid Factor (RF)  may also be elevated in chronic hepatitis, 
any chronic viral infection, leukemia, dermatomyositis, systemic lupous 
erythematosus (SLE), infectious mononucleosis and systemic sclerosis. 
  
ii Anti Nuclear Antibodies. 
Synovial fluid analysis: 
Confirms the presence of inflammatory Arthritis. Fluid may 
show positive Roose-Waaler test in joint fluid, before it can 
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be detected in blood. Also it may show neutrophils or 
monocytes inclusion bodies. 
II. Synovial biopsy: 
Villus formation with thickening of synovial layer and 
infiltration with abnormal cells. 
III. Radiographic Evaluation: 
• Soft tissue swelling 
• Juxta articular osteoporosis 
• Erosion of joint margins 
• joint spaces are decreased 
• deformities 
• atlantoaxial subluxation 
• subchondralerosions and cyst formation 
• fibrous and bony ankylosis develop in the late stages. 
IV. Arthroscopy: 
In acute Rheumatoid Arthritis synovium is oedematous, 
diffusely erythematous and friable. In more chronic 
conditions it becomes thickened. 
V. Renal Biopsy: 
Indicated in cases of reduced tubular or  glomerular function. 
VI. Pulmonary Biopsy: 
Used to distinguish Rheumatoid nodules from carcinoma or 
to establish diagnosis of fibrosing alveolitis. 
 
VII. Ultra sound   
VIII. Scintigraphy 
IX. CT Scanning          - shows cartilage and sub –chondral bone  
damage long before conventional x rays 
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X. MRI 
XI. Urine analysis  
XII. Biochemical analysis 
XIII. Anti CCP antibodies 
 (cyclic citrullinated peptide antibodies) 
XIV. Genetic tests: 
 HLADRB1 Typing to detect the presence of ‘shared epitope’. 
XV. Antinuclear antibody assay (ANA) 
XVI. Bone density test to check for bone loss. 
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DIFFERENTIAL DIAGNOSIS OF RHEUMATOID ARTHRITIS 
Sero negative spondyloarthropathy included following rheumatoid 
like conditions were the serum is negative for rheumatoid factor. They 
are. 
1. Ankylosing spondylitis: 
Ankylosing spondylitis is a chronic, progressive and crippling 
disease affecting the spine. The exact etiology is unclear. Ankylosing 
spondylitis has been found to be more prevalent in certain races and 
hence shows a genetic predisposition. It is related to certain tissue types 
of the human leukocytic antigen (HLA) system. The majority of 
ankylosing spondylitis patient is found to belong to HLA-B27 groups. 
The disease occurs in the 3rd and 4th decades of life and is more 
common in males. The patients present with complaints of diffuse pain in 
the back and vague pain in other joints. 
2.Reiter’s disease: 
Reiter’s disease characterized by triad of polyarthritis, urethritis, 
conjunctivitis. The joint condition is an acute polyarthritis resembling 
rheumatoid arthritis. It does not cause destructive changes in the joint 
structures. The urethritis is non-gonococcal but the exact organism is not 
known. 
3.Psoriatic arthritis 
Psoriatic arthritis is a polyarthritis seen in about  10% of patients 
with psoriasis. 
a. The most common type is the one involving the distal 
interphalangeal joints of the hands and feet with psoriatic nail 
joints. Metacarpophalangeal joints are never involved in psoriatic 
arthritis. 
b. Arthritis multilens is a severe form where there is marked 
destruction of joints. 
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c. Symmetrical polyarthritic type 
d. Oligo arthritic type. 
e. Spondyloarthritic type. 
4.Enteropathic arthritis 
Chronic inflammatory bowel diseases like regional enteritis 
(Crohn’s) disease) and ulcerative colitis are associated with arthritic 
lesion in abour 10% of the cases. There is peripheral (or) involvement of 
the spine. The Joint condition shown remissions and exacerbations along 
with activity of the underlying bowel disease. 
5.Sjogren’s syndrome: 
Sjogren’s syndrome is an immunologic disorder characterized by 
progressive destruction of the exocrine glands leading to mucosal and 
conjuctival dryness (Sicca syndrome) accompanied by a variety of 
autoimmune phenomena. Glandular, when the clinical manifestations are 
within the exocrine system and extra glandular, when other tissues are 
involved as well. 
The disease predominately affects woman in the third of fourth 
decades of life. 
Clinical manifestations: 
i. Keratoconjuctivitis and Xerostomia  
ii. Renal involvement produces mild interstitial nephritis that may 
result in renal tubular acidosis. 
iii. Sensory polyneuropathy and mononeuritis multiplex. 
iv. Pulmonary involvement generally takes the form of an interstitial 
pneumonitis which is usually a little clinical significance. 
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CLINICAL COURSE AND PROGNOSIS: 
 The course of Rheumatoid Arthritis is variable and difficult to 
predict in an individual patient.  Most patients experience persistent but 
fluctuating disease activity accompanied by a variable degree of joint 
deformity. 
 Approximately 15% of patients of R.A. have a short-lived 
inflammatory process that remits without major deformities. 
 According to recent studies,  resuslt published in the BMJ Journals 
of Update of Orthopaedics of 2008 is as follows: 
 ‘Evidence is accumulating that very early rheumatoid arthritis 
(within the first 12 weeks) may be an immunopathologically distinct 
phase of disease.  Thus, a “window of opportunity” may exist within the 
first 12 weeks of disease, during which introducing DMARDs(Diseasse 
Modifying Anti Rheumatic Drugs) may have different effects than 
treatment at a later date, including prevention of erosions and possibly 
complete switching off of the disease.’ 
COMPLICATIONS 
Septic Arthritis: 
 It may complicate Rheumatoid Arthritis, particularly in patients 
with long-standing nodular sero-positive disease.  In debilitated patients, 
fever and leucocytosis may be absent and the signs of infection limited to 
malaise and slight exacerbation of inflammation in one or more joints. 
 Staphylococcus aureus is commonly implicated secondary to 
invasion from an ulcerated nodule or infected skin lesion. 
Amyloidosis: 
 It is a complication of prolonged active disease and is formed in 
25% to 35% of patients at autopsy, making Rheumatoid Arthritis a 
leading cause of secondary amyloidosis. 
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Other Complications: 
1. Fixed deformities. 
 The perils often the common place ones resulting from ignorance 
and neglects.  Early assessment and planning should prevent postural 
deformities that will result in joint contractures. 
2. Muscle weakness 
 Even mild degree of myopathy or neuropathy when combined with 
prolonged inactivity may lead to profound muscle wasting and 
weakness.  This should be prevented by physiotheraphy and pain 
control if possible.  If not the surgeon must be forewarned of the 
difficulty of postoperative rehabilitation. 
3. Joint rupture 
Occasionally the joint lining ruptures and synovial contents spill 
into the soft tissue.  Treatment is directed at the underlying synovitis i.e 
splintage and injection of the joint synovectomy as a second resort. 
4. Spinal cord compression 
It is a rare complication of cervical spine instability.   By the onset 
of weakness Upper Motor Neuron (UMN) signs in the lower limb is 
suspicious.  If they occur, immobilization of the neck is essential and 
spinal fusion should be carried out as soon as possible. 
5. Systemic vasculitis 
This is a rare but potentially serious complication. High doses of 
corticosteroids and Intra Venous (I.V) plasma volume expanders may 
be called for. 
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JUVENILE RHEUMATOID ARTHRITIS 
 Juvenile rheumatoid arthritis (J.R.A) is one of the more common 
connective tissue diseases of children and is a major cause of functional 
disability in this age group.  By definition, it begins before the age of 16 
and most patients are diagnosed early childhood.  There is 2:1 female 
predominance except in the subgroup that has a systemic onset, in which 
the sexes are equally affected. Juvenile rheumatoid arthritis (J.R.A) 
differs from Rheumatoid Arthritis(R.A.) in adults.   
In that 
1. Oligo arthritis is more common. 
2. Systemic onset is more frequent. 
3. Larger joints are affected more than smaller joints. 
4. Rheumatoid nodules and rheumatoid factor are usually absent 
and 
5. Antinuclear antibody seropositivity is common. 
Genetic susceptibility, abnormal immuno regulation, cytokine  
production and viral infection may all play a role in the pathogenesis.  
The morphology of the joint, pathology, including marked synovitis is 
similar to the alteration in adult Rheumatoid Arthritis.  The development 
of symptoms, such as fatigue,  joint stiffness and limited range of motion 
is generally slow and gradual.  Commonly targeted joint in all forms of 
the disease are the knees, wrists, elbows and ankles.  They become warm 
and swollen and are often involved symmetrically, Pericaridtis, 
myocaridtis, pulmonary fibrosis, glomerulonephritis, uveitis and growth 
retardation are potential extra-articular manifestations.  A systemic onset 
may begin rather abruptly, associated with high spiking fevers, migratory 
and transient skin rash, hepatomegaly, spleenomegaly and serositis.  
Satisfactory recovery occurs in 70 to 90% of patient and in only 10% 
severe joint deformities present. 
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MANAGEMENT 
 
 Unproven remedies are frequently being sought after and are 
frequently reported in the lay literature.  Calcium and vitamin D have 
been proven to be beneficial in the treatment of osteoporosis (low bone 
density).  Osteoporosis is frequently seen in patients with rheumatoid 
arthritis and is a side effect of steroid treatment. 
Surgery: 
 The role of surgery is mainly reconstructive or rehabilitative.  The 
following procedures are used, in the management of Rheumatoid 
Arthritis. 
1. Synovectomy 
2. Capsulotomy 
3. Osteotomy 
4. Arthrodesis  
5. Arthroplasty-Excision and Replacement. 
Adjunctive treatments: 
Rehabilitation: 
 Restoration of a disabled individual to perform function to a 
normal or near normal manner is called Rehabilitation. 
 Rheumatoid Arthritis is a crippling disease.  Hence the Rheumatoid 
Arthritis patients require rehabilitative measures that include physical 
therapy, and special splints and appliances to help them and manage their 
own self care activities like dressing and eating. 
Physiotherapy: 
 Physiotherapy is the application of physical agents and principles 
to pathological conditions for the purpose of producing therapeutic 
effects. 
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Physiotherapy includes: 
 1. Active exercise  
2. Passive joint movements  
3. Local heat   
4. Massage   
5. Electrical stimulation of muscles  
6. Ultra sound therapy  
7. Light therapy, ultraviolet rays and infrared rays. 
Exercise therapy: 
 Once inflammation is satisfactorily controlled, appropriate and 
regular exercises are essential to strengthen muscles weakened by 
disease.  Rheumatoid arthritis often makes joints stiff and restricts their 
motion if they are not used regularly.  Exercises are designed to meet the 
needs of each patient and should be monitored by professionals 
specializing in physical medicine. 
Exercise guidelines: 
1. The patient is advised to engage in low – impact exercises like 
stationary cycling, rowing and water aerobics and,  
2. Start with low intensity exercise. 
3. During periods of inflammation or pain (for rheumatoid arthritis), 
reduce exercise intensity and duration. 
4. Patient need longer than normal (longer than ten minutes) warm 
ups and cool downs. 
5. Modify patients exercise intensity or duration depending on how 
the patient feel that day. 
6. It is important that patient should move his joints through a full 
range of motion at least once a day, otherwise, joints will become 
stiff. 
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7. If the patient experience pain two hours after exercise, he need to 
adjust the intensity or the duration of the exercise. 
8. The patients should do exercise to the point in he can (unless he 
have hypertension) because these type of exercises put the least 
amount of stress on the joints. 
9. Patient should use isometric exercises when he can (unless he have 
hypertension) because these types of exercises put the least amount 
of stress on his joints. 
10. Advise the patient to consult the doctor if he experience severe 
pain after exercise. 
Active exercise is given to: 
 Mobilize joints, strengthening muscles, Improve co-ordination or 
balance. 
Passive joint movements: 
 The chief use of passive joint movement is to preserve full mobility 
when the patient is unable to move the joint actively. 
TYPES OF EXERCISES: 
 Range – of – motion Exercise, Strengthening Exercise, Limbering 
up Exercise: 
1. Range – of – Motion Exercises / Stretching Exercises: 
 Stretching exercise involve moving a joint as it will comfortably 
go through its full range of motion or stretch.  This exercise help to 
maintain normal joint movement or restore movement that has been lost. 
Clinical  Assessment of Joint Motion: 
 The most widely used and recommended instrument is the 
universal Goniometer, sometimes called an Arthrometer.  Basically, it is 
protractor, to the center of which two long slender arms or levers are 
attached.  Usually only one of the arms is movable, but may variations in 
design are possible. 
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2. Strengthening Exercise: 
 Strengthening exercises help to maintain or increase the strength 
and power of the muscles. 
3. Limbering up Exercises: 
 Help to reduce morning stiffness or stiffness after staying in one 
position too long by doing the Range – of – motion exercises each day 
only a few times of loosen up. 
 
Details of Range – of – motion Exercises: 
Upper Extremities – Shoulder: 
1. Arms at side with elbow straight, bring arms forward upward 
by year. 
2. Arms at side with elbow straight, take arms sideward upward. 
3. Arms at side bend elbows to right angle and take hands apart. 
Elbow: 
1. Bend elbow, touching fingers to top of shoulder. 
2. Straighten elbow. 
Fore arm: 
1. Elbows bent, turn palm of the hand and then back of the hand 
towards face. 
Wrist: 
1. Keeping forearm steady, move the wrist up and down as in 
waving. 
2. Again hold forearm steady, mover the wrist up and down as in 
hand shaking. 
3. Make circle with hands. 
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Hand and fingers: 
1. Make tight first. 
2. Open fingers as wide as possible. 
3. With the hand open spread fingers away from each other and 
then together. 
4. Touch tip of the thumb to the tip of each finger. 
5. Bend the thumb in toward palm of the hand. 
Lower Extremities: 
Knee: 
 Sit with your feet off the floor.  Lift the leg and then allow it to 
return of the bent position slowly. 
Ankle: 
1. Pull foot up and in, and then push back down. 
2. Make circle with foot. 
3. Pull foot in toward other foot. 
4. Pull foot to outside. 
Toes: 
1. Pull up on toes then curl toes under. 
Exercises for the Neek: 
1. In the sitting position, twist your head as far as possible in 
each direction. 
2. Sit or stand with your hands on the hips.  First circle the head 
clockwise, then counter clockwise. 
3. In the sitting position, try to touch each shoulder with your 
head. 
4. In the sitting position look behind as far as possible and then 
look at your toes. 
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Exercise benefits for individuals with Arthritis: 
1. Helps to preserve muscle strength and normal mobility of 
joints. 
2. Relieves pain and stiffness. 
3. Prevents further deformities. 
4. Improves over-all physical fitness. 
5. Improves coordination. 
Heat and Cold Treatment: 
 Head and cold treatment effective means of relaxing muscles and 
relieving pain in arthritis joints.  A hot bath, hat pads, paraffin wax and 
cold compresses are some methods frequently used. 
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SELF MANAGEMENT TECHNIQUES FOR 
RHEUMATOID ARTHRITIS 
 
Self management is the most important aspect of the treatment of 
Rhematoid arthritis 
 
The Ten Self Help Techniques 
1. Positive mental attitude     
The patient is told to focus on thins other than pain and their own 
body.  They are encouraged to think positively. 
2. Regular medication: 
        The patient is told the value  of regular and correct medication. 
3. Regular exercises : 
The patient should follow a regular and appropriate exercise 
programme, most suited for themselves. 
4. Use of joints:   
The patient is told the value of correct posture and the methods of 
using the joints. 
5. Energy conservation:  
Patients are instructed to listen to the body ‘inner signals’ for rest. 
Slowing down and avoiding too many activities reduce the stress 
and strain on the joints. 
6. Assistive devices:  
Devices like splints, braces and walking sticks can help stabilize 
the joints, provide strength and reduce pain and inflammation. 
7. Adequate sleep:  
A good adequate sleep provides rest to the ailing joints and reduces 
the pain and swelling. 
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8. Massage:  
A Good moderate massage brings warmth and relieves  pain due to 
arthritis. 
9. Relaxation techniques: 
Relaxation techniques like yoga, meditation, etc, help to relax the 
muscles, mind and controls respiration heart rate and blood 
pressure. 
10. Modification in the daily activities 
♣ Using western toilets 
♣ Bath aids and railings 
♣ long handle broom stick and mob to clean the floors. 
♣ Use of walking sticks while walking, climbing high chairs 
♣ Avoid squatting on the ground for food. 
♣ To avoid squeezing the clothes. 
♣ To avoid walking on hard and uneven and rough surfaces. 
♣ To sleep on hard surface. 
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RESEARCH UPDATES OF RHEUMATOID ARTHRITIS 
 
 Rheumatoid arthritis is associated with abnormal lipoprotein 
patterns, especially low levels of high density lipoprotein cholesterol 
(also referred to as HDL or "good" cholesterol). 
 Rheumatoid arthritis patients have a higher risk of premature 
cardiovascular disease. Since they have an increased risk of heart attacks, 
stroke, and premature death -- it is important to do all that is possible to 
improve heart health -- especially since rheumatoid arthritis patients are 
limited in what they can do to modify risk factors through exercise.  
 Taking oral contraceptives also failed to reduce the risk of RA. 
It's been suspected that oral contraceptives offer protection against the 
disease because they contain hormones that are elevated during 
pregnancy. 
 Effect of RA on fertility: RA does not appear to affect the 
likelihood of fertility; however, lower birth rates among women with RA 
have been reported. This may reflect choices by women to limit family 
sizes, as a recent study found that women diagnosed with RA prior to the 
birth of their first child had the fewest pregnancies and children.  
 Effect of RA on pregnancy: Few studies have addressed the 
effects of RA on pregnancy. A 2006 study suggests that RA during 
pregnancy does not affect the rate of spontaneous abortion.12  
 Effect of RA on fetal outcome: There has been some 
controversy regarding fetal complications in mothers with RA; however, 
a 2006 study showed an increased risk for prematurity but no increased 
risk for low birth weight after adjusting for gestational age. In contrast, 
another 2006 study did show an increased rate of intrauterine growth 
restriction associated with RA.  
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 Women who breastfeed for more than a year reduce their 
chance of rheumatoid arthritis by half, research suggests. 
 Testosterone may improve the general wellbeing of 
postmenopausal women with active rheumatoid arthritis. 
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MATERIALS AND METHODS 
 
The dissertation work on Uthera Vatha Suronitham was carried out 
during the year of 2008 - 2010 at the Post Graduate Department of 
Sirappu Maruthuvam, Govt. Siddha Medical College, Palayamkottai. 
 
Selection of Patients: 
 For the clinical study 20 patients suffering from Uthera Vatha 
Suronitham, were admitted in the inpatient ward of Government Siddha 
Medical College, Palayamkottai of both sexes and varying age groups 
and 20 patients were treated as out patients. 
 This study has been done mainly based on clinical symptoms and 
certain criteria like nutritional status, seasonal variations, economic 
status, family history and other significant diseases are also been 
considered.  The confirmation of clinical diagnosis was made on both 
Siddha and Modern aspects. 
 
Investigations: 
 The symptoms of Uthera Vatha Suronitham more or less correlates 
with Rheumatoid arthritis in modern medicine. In Siddha aspect the 
diagnosis was made under the following criteria. 
1. Mukkutra nilai 
2. Ennvagai thervu 
3. Udal kattukal 
4. Kalam 
5. Nilam 
6. Neer kuri 
7. Nei kuri 
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In modern aspects the routine laboratory investigations were made. 
Haematological investigations: 
1. Total W.B.C. count. 
2. Differential W.B.C. count. 
3. Erythrocyte sedimentation rate. 
4. Haemoglobin percentage. 
5. Blood Sugar. 
6. Blood Urea. 
7. Serum Cholesterol. 
Urine Analysis: 
1. Albumin 
2. Sugar 
3. Deposits 
Motion Analysis: 
1. Ova 
2. Cyst 
Specific investigations: 
 1.Rheumatoid factor. 
 2.Radiographic evaluation. 
Management: 
 The drugs were selected after a detailed study of various siddha 
literatures. They are 
1. Nkfehjp nkOF (Meganathee Mezhugu) 
2. Kf;$l;L vz;nza; (Mukkuttu Ennai) 
The pharmacological study and the bio chemical study of both the 
drugs were conducted at the Department of pharmacology, Department of 
BioChemistry, Govt. Siddha Medical College, Palayamkottai 
respectively. 
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OBSERVATION AND RESULTS 
 
Results were observed with respect to the following criteria. 
 
1. Sex 
2. Age 
3. Occupation 
4. Food habits 
5. Economic status 
6. Mukkutra kaalam 
7. Paruva Kaalam 
8. Thinai 
9. Mukkutra theory 
10. Udal Kattugal 
11. Enn vagai thervugal 
12. Neikuri 
13. Duration of illness 
14. Onset of disease 
15. Clinical features 
16. Results 
 
1.Sex distribution: 
S.No. Sex No.of Cases (out of 20) % 
1. Male 1 5% 
2. Female 19 95% 
Total  20 100% 
Out of the twenty patients, 1 was  male  (5%) and 19 (5%) were 
females. 
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2.Age distribution: 
 
S.No Age (inyears) No.of Cases % 
1. 21 -30 3  15% 
2. 31 -40 2 10% 
3. 41 -50 8 40% 
4. 51 -60 6 30% 
5. 61 and above 1 5% 
The percentage, was highest in the age group of 41 – 50 (40%) and 
30% in 51 – 60 and the least percentage was above 61 years (5%) among 
the studied cases. 
3.Occupation:  
S.No Occupation No.of Cases % 
1. Skilled workers 1 5% 
2. Manual labours 4 20%
3. Others 15 75%
 
In percentage of occupation, 1% were skilled workers, 20% were 
manual labours and 75% were others. 
 
4. Food Habits: 
S.No Food Habits No.of Cases % 
1. Vegatarian 3 15% 
2. Mixed 17 85% 
 According to food habits, 85 % of the cases had mixed diet and 
15% were vegetarians. 
  
81 
 
 
5. Socio – economic Status: 
 
S.No Socio economic status No.of Cases % 
1. Poor 15 75% 
2. Middle class 5 25% 
3. Rich - - 
  
According to the study, 70% of the cases belonged to poor class 
economic status. 
 
6. Mukkutra kaalam: 
S.No. Kalam No.of cases Percentage Total percentage
1. 
Vatham 
0-11 - - 
15% 11-22 - - 
22-33 3 15% 
2. 
Pitham 
33-44 4 20% 
85% 44-55 12 60% 
55-66 1 5% 
3. 
Kabam 
66-77 - - 
0% 77-88 - - 
88-100 - - 
 
 Among the twenty cases, 85% of the cases were under pitha 
kaalam and 15% of the cases were under vatha kalam. 
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7.Paruva kaalam: 
S.No. Paruva kaalam No.of Cases % 
1. 
Elavenil (chithirai – Vaikasi) 
April 15 – June 15 
0 - 
2. 
Muthuvenil (Aani – Aadi) 
June 15 – August 15 
5 25% 
3. 
Kaar (Aavani – Purattasi) 
August 15 – October 15 
7 35% 
4. 
Koothir (Ippasi – Kaarthikai) 
October 15- December 15 
7 35% 
5. 
Munpani (Markazhi – Thai) 
December 15 – February 15 
1 5% 
6. 
Pinpani (Maasi – Panguni) 
February 15 – April 15 
0 - 
 
 Under paruva kalam, the incidence was 35% noted in Kaar Kaalam 
and Koothir Kaalam and 25% was noted in Muthuvenil Kaalam. And 5% 
was seen in Munpani Kaalam. 
 
8.Thinai: 
 
S.No. Thinai No.of Cases % 
1. Kurinji - - 
2. Mullai - - 
3. Marutham 20 100 
4. Neithal - - 
5. Paalai - - 
Total  20 100 
 
 All the twenty cased belonged to Marutha nilam 
83 
 
 
9.Mukkutra theory: 
A. Derangement in the types of vatham:- 
S.No. Types of Vatham No.of Cases % 
1. Pranan - - 
2. Abanan 10 50 
3. Viyanan 20 100 
4. Uthanan - - 
5. Samanan 15 75 
6. Naagan - - 
7. Koorman - - 
8. Kirukaran - - 
9. Devathathan 12 60 
10. Dananjeyan - - 
  
According to the derangement in the types of vatham, 50% of the 
cases abanan was affected, viyanan was also affected in 100% of the 
cases, samanan was also affected in 75% of the cases and devathathan 
were affected in 60% of the cases. 
B.Derangement in types of  Pitham:  
 
S.No. Types of Pitham No.of Cases % 
1. Analam 15 75 
2. Ranjakam 12 60 
3. Saathakam 15 75 
4. Prasakam - - 
5. Aalosakam - - 
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Among the cases studied, analam pitham was affected in 75% of 
the cases and Sathaka Pitham was affected in 75% of the cases and 
Ranjakam was affected in 60% of cases. 
 
C. Derangement in types of kabam: 
 
S.No. Types of Kabam No.of Cases % 
1. Avalambakam - - 
2. Kilethakam 15 75 
3. Pothakam - - 
4. Tharpakam - - 
5. Santhikam 20 100 
  
Among the 20 cases,  kilethakam was affected in 75% of cases, 
santhikam was affected in 100% of the cases. 
 
10. Udalkattugal 
 
S.No. Udalkattugal No.of Cases % 
1. Saaram 20 100 
2. Senneer 12 60 
3. Oon 3 15 
4. Kozhuppu 18 90 
5. Enbu 18 90 
6. Moolai - - 
7. Sukkilam/ Suronitham - - 
85 
 
 
  
Among the 20  cases, saaram were found affected in 100% of the 
cases and enbu was seemed to be affected in 90% oifcases senneer was 
affected in 60% of the cases and in 15% of the cases oon was affected. 
 
11. Ennvagai thervugal: 
 
S.No. Enn Vagai Thervugal No.of Cases % 
1. Naa 5 25 
2. Niram 10 50 
3. Mozhi - - 
4. Vizhi 10 50 
5. Sparisam 20 100 
6. Naadi 20 100 
7. Malam 10 50 
8. Moothiram 5 25 
  
Naadi  was observed in all the 20 cases. Of them 10 cases had 
Vatha Naadi and 5 cases had Pitha naadi.  Other 5 cases had Thontha 
naadi Vathapitha naadi.   
 
 Naadi No of pts. Percentage %
1. Vatham 10 50 
2. Pitham 5 25 
3. Vathapitham 5 25 
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Among the cases studied, sparism, naadi and were affected in 
100% of the cases. Niram, Vizhi, Malam were affected in 50% of the 
cases and Naa, Moothiram were affected in 25% of the cases. 
12. Neikuri: 
S.No. Character of Neikuri No.of Cases % 
1. Spreads slowly 4 20 
2. 
Spreads like 
 Salladaik kan 6 30 
3. 
Spreads like  
Pearl 
5 25 
4. 
Spreads in  
improper shape 
5 25 
 
In 30% of the cases Neikuri spreads like Salladaikkan,  
In 25% of the cases Pearl like neikuri was noted.  
In 20% of cases it spreads slowly on the surface and in 25% of 
cases improper shape was noted. 
 
13. Duration of the illness: 
 
S.No. Duration of illness No.of Cases % 
1 1 month – 3 months 2 10 
2. 3 month – 6 months 6 30 
3. 6 months – 1 year 4 20 
3. 1 year – 3 years 6 30 
4. 3 years and above 2 10 
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Out of 20 cases, 30% of the cases were affected  between 3 to 6 
months and 20% were between 6 months to 1 year and 30% were 
between 1 to 3 years.  And 10% were affected chronically more than 3 
years. 
14. Onset of the disease: 
S.No Mode of onset No. of cases % 
1. Sudden 4 20% 
2. Gradual 16 80% 
 
According to the study, 80% of the cases had gradual onset of 
disease and 20% had sudden onset. 
 
15. The clinical features: (Symptoms) 
S.No. Symptoms No.of Cases % 
1. Joint pain 20 100 
2. Swelling 20 100 
3. Morning stiffness 20 100 
4. Restricted movements 14 70 
5. Difficulty in chewing 0 - 
6. Difficulty in walking 10 50 
7. Neck pain 5 25 
8. Sleeplessness 12 60 
9. Fever 5 25 
10. Loss of appetite 15 75 
11. Loss of weight 3 15 
12. Constipation 10 50 
13. Giddiness 2 10 
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 Among the 20 patients, 100 % of the cases had joint pain, swelling 
and morning stiffness. 75 % of the cases had restricted movements. 
Clinical features (Signs) 
S.No. Signs No.of Cases % 
1. Subcutaneous nodules - - 
2. Muscle wasting 2 10 
3. Opthalmic manifestation - - 
4. Hepatomegaly - - 
5. Spleenomegaly - - 
6. Anaemia 12 60 
7. Tenderness 20 100 
 
Out of the 20 Cases, 100% of the cases had tenderness and 60% of 
the cases were anaemic and 10% of the cases had muscle wasting. 
Grading of pain, joint swelling and restricted movements: 
S.No. Symptoms 
No.of Cases 
% 
Mild Moderate Severe 
1. Pain 3(15) 10 (50) 7 (35) 100 
2. Joint swelling 2(10) 13 (65) 5 (25) 100 
3. Restricted movements 4(20) 5 (25) 5 (25) 70 
4. Muscle wasting 2 (10) - - 10 
 
All the 20 Cases(100%) had pain and joint swelling and 70% with 
restricted movements and 10% of the cases had muscle wasting. 
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Involvement of locomotor system 
Table showing involvement of  extremities 
S.No. 
Mode of  onset 
No.of Cases % 
Early Late 
1. Upper extremities Lower extremities 15 75 
2. 
Lower 
extremities 
Upper extremities 3 15 
3. Both extremities  2 10 
 
Out of the 20 Cases 75 % of the cases had involvement of the 
upper extremities first and then the lower extremities. 15% of the cases 
had involvement of the lower extremities first and then the upper 
extremities.  In 10% of the cases both extremities were involved. 
The joint involvement: 
S.No. Joints involved No.of Cases % 
1. Proximal interphalangeal joints of hand. 20 100 
2. Metacarpophalangeal joints 20 100 
3. Wrist joint 15 75 
4. Elbow 4 20 
5. Shoulder 6 30 
6. Temporomandibular jt - - 
7. Sternoclavicular jt. 2 10 
8. Cervical spine 1 5 
9. Hip joint 1 1 
10. Knee joint 15 75 
11. Ankle Joint 10 50 
12. Metatarsophalangeal Jt 2 10 
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Out of the cases, 100 % of the cases had proximal interphalangeal 
joint and metacarpophalangeal joint involvement. 75 % had wrist joint 
involvement and knee joint involvement. 50% had ankle joint 
involvement.  30% has shoulder joint involvementand 10% 
metatarsophalangeal joint involvements. 
 
Table showing deformities of the joints 
 
S.No. Deformities No.of Cases % 
1. Interphalangeal joints 1 5 
2. Metacapophalangeal joints 1 5 
3. Wrist joint 1 5 
4. Elbow joint 1 5 
5. Shoulder joint - - 
6. Hip joint - - 
7. Knee joint - - 
8. Ankle joint - - 
9. Metatarsopahalangeal joint - - 
10. Spine - - 
 
Out of the 20 cases studied 5% of the cases had deformities in the 
elbow joint, wrist joint, meta carpophalangeal joint and interphalangeal 
joint. 
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The Grading of Rheumatoid arthritis: 
Grade I - No restriction of ability to perform normal activities 
Grade II - Moderate restriction but with ability to perform most  
of the  daily activities. 
Grade III - Marked restriction with an inability to perform daily
 activities. 
Grade IV - Incapacitation with confinement to bed. 
 
Table for grading of R.A. 
S.No. Grade No.of Cases % 
1. I 6 30 
2. II 7 35 
3. III 5 25 
4. IV 2 10 
 
Among the 20 Cases, 35% of the cases were under grade II and 
30% of the cases were under grade I and 25% of the cases belonged to 
grade III and 10% of the cases belonged to grade IV. 
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16.Results: 
S.No. Results No.of Cases Percentage 
1. Improved 4 20 
2. Partially improved 14 70 
3. No improvement 2 
10 
 
 
Improved  : Complete subsidence of pain and Swelling 
Parially Improved : Relief of pain, reduction in swelling and  
increased range of movements 
No Improvement :- Persistance of pain, Swelling and other signs 
  and symptoms. 
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DISSCUSSION 
 
Siddha system of medicine classifies the diseases into 4448 types 
Among them Yugi vaidhaya chinthamani has classified Vatha diseases 
into 80 types. Among the 80 types, Uthera Vatha Suronitham is one of 
the diseases that results in both the major and minor joints involvement.  
 Twenty cases of Uthera Vatha Suronitham were admitted in the 
Post graduate Sirappu Maruthuvam inpatient ward, Govt. Siddha Medical 
College, Palayamkottai.  
For diagnostic purposes the parameter used in siddha aspect were 
Porial arithal, Pulanal arithal, Vinaathal, Kanmendriyam, Gnanendriyam, 
Uyir Thathukkal, Udal Thathukal, Ennvagai Thervugal, Neerkuri, Neikuri 
etc. 
 The modern parameters used were criteria for the diagnosis of 
Rheumatoid arthritis, laboratory investigations, radiological evaluation 
etc. 
The sex distribution: 
 Out of the twenty patients 1 (5%) cases was male and 19(85%) 
were females.  
The age distribution: 
 Among the 20 cases, 15% belonged to the age group of 21 -30 
years. 10% of the cases were between 31 - 40 years. 40% of the cases 
were between 41 -50 years.  30 % of the cases were between 51 -60 years 
5% of the cases were above 61 years. 
 From the above data, the incidence of the disease seems to be more 
in the age group of 41 -50 years, and the next is between 51 - 60 years. 
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The kaalam: 
 The patients in Vaatha kalam were 15%.  85% of the patients were 
of pitha kalam and no cases were of kaba kalam. According to Siddha 
concept maximum number of cases were noted to be in pitha kalam 
which is between 33 to 66 years, which co – ordinates with modern 
concept of the incidence in 4 th – 5th decade. 
The paruva kalam: 
 Among the 20 cases 35% of the cases were seemed to develop the 
disease during Karkaalam(Aavani – Purattasi) and Koothir kaalam(Ippasi 
– Kaarthikai) and 25% of the cases found in Muthuvenil Kaalam (Aani – 
Aadi). 5% of cases developed during Munpani (Margali  - Thai). 
The Thinai: 
All the 20 cases were belonged to Marutha nilam. Even though as 
per siddha literatures, Marutha nilam is said to be free from diseases, here 
the patients developed diseases due to alteration in their food habits and 
routine activities. 
The socio – economic status: 
 75% of the cases were under poor class, where as 25% of the cases 
belonged to middle economic groups. 
The aetiological factors: 
 5% of the cases had positive family history.  Literary evidences 
shows that Uthera Vatha Suronitham may develop  due genetic 
predisposition. 
The onset of disease: 
 The mode of onset was acute in 15% and gradual onset in 85%  of 
the cases. Thus the incidence of the disease with gradual onset is more, as 
per literatures. 
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The clinical manifestations: 
 The patients with Uthera Vatha Suronitham (R.A.) present with 
articular manifestations with or without extra articular manifestations 
were noticed. 
 100 % of the cases had joint pain, swelling and morning stiffness. 
70% of the cases had restricted movements and 40% of the cases had 
difficulty in walking. 5% of the cases had pain in the neck. The joint in 
all the cases experienced early morning stiffness for about 2-3 hours. 
Decreased movements of the joints noticed in all the cases which was 
assessed by asking the patient to move the joint in particular direction. 
Involvement of upper and lower extremities: 
 The incidence of initial involvement of joints of the upper limb was 
noticed in 75 % of the cases. 15%  of the cases, showed involvement of 
the lower limbs, while 10% of the cases showed involvement of upper 
and lower limbs simultaneously. 
Involvement of individual joints: 
100 % of the cases had proximal interphalangeal joint and 
metacarpophalangeal joint involvement. 75% had wrist joint involvement 
and knee joint involvement. 50% had ankle joint involvement.  30% has 
shoulder joint involvementand 10% metatarsophalangeal joint 
involvements. 
 
Deformities of joints: 
 5% of the cases had deformities in the elbow joint, wirst joint, 
metacarpophalangeal joint and interphalangeal joint. 
Elicitation of extra articular manifestations: 
 Besides the articular symptoms certain signs which include the 
examination of the enlargement of liver and spleen were carried out. 
Examination of respiratory system, cardio vascular system, were also 
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carried out. Opthalmic manifestation were also noted. Either 
hepatomegaly or spleenomegaly was not present in any of the cases. 
Likewise respiratory and cardio vascular manifestation and ophthalmic 
manifestation were not present. Rheumatoid nodule cannot be elicited 
among these cases. 
Uyir thathukkal: 
 Uyir thathukkal include 3 vital humours namely 
Vatham 
Pitham  
Kabam 
The derangement in any of the above three causes diseases. They were 
noticed in the 20 cases and are discussed below. 
Vatham: 
 Viyanan was affected in 100% of the cases. Abanan was affected in 
50% of the cases Samanan was affected in 75 % of the cases. 
 When Abanan is affected it produces constipation, the disturbance 
in Viyanan produce pain, swelling and restricted movements of the joints 
and if Samanan is affected there is loss of appetite. 
 Devathathan was affected in 60% of the cases resulting in 
sleeplessness. 
Pitham: 
Anala pitham was affected in 50% of the cases. Saathaga pitham 
affected in 75% of the cases and Ranjakam  was affected in 60% of the 
cases. 
 Affected Anala pitham produce loss of appetite. Ranjakam, when 
affected produces decrease in haemoglobin and affected saathaga pitham 
produce restriction of movements 
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Kabam: 
 Santhigam was affected in 100% of the cases. Kilethagam was 
affected in 75% of the cases.  
 Affected Kilethagam produce loss of appetite and affected 
Santhigam produce joint pain, swelling and restriction of movements. 
Udalkattugal: 
 Among the 20  cases, Saaram was found affected in 100% of 
the cases and Enbu was seemed to be affected in 90% of cases Senneer 
was affected in 60% of the cases and in 15% of the cases Oon was 
affected and 90% of cases were affected in Kozhuppu thathu. 
 When Saaram is affected it produces general debility, fatigue, 
synovial swelling.  In Senneer affected cases, Haemoglobin percentage 
was found  reduced and ESR was increased  in level.  Oon affected cases 
shows mild muscular wasting.  Kozhuppu thathu affected cases showed 
disability in using joints.  Enbu affected cases shows severe restriction of 
movements and in severe conditions they show cartilage destruction and 
bony erosion by radiological investigations.   
 
Ennvagai thervgal: 
 Naadi  was observed in all the 20 cases. Of them 10 cases had 
Vatha Naadi and 5 cases had Pitha naadi.  Other 5 cases had Thontha 
naadi Vathapitha naadi.   
 Sparism was affected in all the cases which showed joint 
tenderness, warmthness over the inflammed joints. 
 Malam was affected in 50% of cases and they had constipation. 
 Naa was affected in 25% of the cases and the tongue was coated 
and was pale in colour due to anaemia. 
 Niram and vizhi were affected in 50% of the cases and showed 
anaemic manifestations. 
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Neikuri: 
In 30% of the cases Neikuri spreads like Salladaikkan that denotes 
this disease is curable.  
In 25% of the cases Pearl like neikuri was noted that denotes Kaba 
neer.  
In 20% of cases it spreads slowly on the surface that said it is a 
curable disease and in 25% of cases improper shape was noted. 
 
Grading of Vali azhal keel vayu patients: 
Grading of Rheumatoid arthritis was useful to assess the severity of 
the disease. 
Grade 1:  
 No restriction of ability to perform normal activities. 
Grade II:  
 Moderate restriction but with an ability to perform most of the 
daily activities. 
Grade III: 
 Marked restriction with an inability to perform most of the daily 
activities. 
Grade IV: 
 In capactitation with confinement to bed. 
In this study, 
30%  of the cases belonged to Grade I 
35% of the cases belonged to Grade II 
 25% of the cases belonged to Grade III 
 10% of the cases belonged to Grade IV. 
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Investigations: 
Besides siddha based investigations since the disease has been 
compared with Rheumatoid arthritis, investigations meant for 
Rheumatoid arthritis were also done.  
Routine examination of blood, urine and stools were done during 
the admission and the discharge. 
Examination of urine and stools showed no abnormalities. 
Examination of blood showed 60% of the cases showed decreased 
in haemoglobin percentage and  increased ESR level. 
 Rheumatoid arthritis factor was positive in ten cases.  
Blood sugar, Blood urea and Serum cholesterol were done in the 
Biochemistry Department Govt. Siddha Medical College, Palayamkottai. 
The values were found normal in all the cases. 
The patients were also subjected to radiological evaluation which 
revealed R.A. 
 
The management: 
 Siddha system of medicine follows certain criterias in the 
management of the diseases. 
 “Viraesanathal vatham thazhum” 
 This shows that before treating vatha diseases, laxatives or 
purgatives can be administered  to correct altered Vatham. 
 Uthera vatha Suronitham is under Vatha diseases, so all the 20 
cases were given Vellai Ennai – 30 ml was administered once at early 
morning  with empty  stomach for purgation. 
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 From next day onwards, the trial drug Meganathee Mezhugu – 
130 mg (Nkfehjp nkOF) two times per day with palm jaggery after 
meals was given with Palm jaggery as adjuvant. 
 The external drug Mukkuttu Ennai (Kf;$l;L vz;nza;) was 
given to apply in all the painful major and minor joints. 
 Along with them, the fomentation (xw;wlk;) with Lemon piece 
soaked in Gingelly oil, was also adviced so that the increased venous and 
lymphatic drainage will cause reduction of swelling. 
Clinically the drugs were free from side effects.  
In the initial stage all the patients were advised to take bed rest. 
After the severity of symptoms had reduced, they were advised to do 
some exercises. 
The patients were observed  carefully when they were performing 
the exercises. Care was taken for patients to perform exercise slowly 
without any strain. 
Assessment of the effects of management: 
 All the 20 cases were treated with ‘Nkfehjp nkOF” 
(Meganathee Mezhugu) internally and ’Kf;$l;L vz;nza;” 
(Mukkuttu Ennai) externally. Ottradam was also advised.  
The results of treatment was assessed on the basis of reduction in 
symptoms such as pain, joint swelling, and a sense of well being. The 
patients were treated for about 10 to 60 days.  At the end of the treatment 
the results were discussed as follows:  
Improved, Partially improved and No improvement. 
20% of the cases improved well. 
70% of the cases were partially improved and 
10% of the cases showed no improvement. 
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 At the end of the treatment there was a rise in Hb level and 
decreased in ESR level in all the cases.  
After discharge the patients were advised to attend the Post 
Graduate Department of Sirappu Maruthuvam O.P. for further follow up. 
  
Advice to the patients: 
¾ During the course of treatment diet restrictions was strictly advised.  
¾ To take plenty of Protein rich diet like Green gram and calcium 
rich diet like milk and Palm jaggery. 
¾  Patients were advised to take preventive measures like avoiding 
exposure to chill weather. 
¾ To take bath in warm water. 
¾ To keep the mind peaceful by practicing Yogasanam, Pranayamam, 
Dhyanam. 
¾ To advice the patient and their family to understand about the 
characters of disease and to keep the mind accordingly. 
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SUMMARY 
 
Uthera Vatha Suronitham is one among a common problem in 
clinical practice mostly affecting the females. It has received an 
international attention in search of finding out of a new drug for the 
complete cure of the disease. 
 Uthera Vatha Suronitham is a chronic multi system connective 
tissue disorder of unknown aetiology. The characteristic feature of 
Rheumatoid arthritis is persistant inflammatory synovitis usually involve 
the peripheral joints in a symmetrical fashion. The potential of the 
synovial inflammation to cause cartilage destruction and bone erosion 
and subsequent joint deformity is the hall mark of the disease. 
Joint pain, Swelling, tenderness which may be aggravated on 
motion. Morning stiffness of 2 to 3 hours duration, easy fatiguability, 
anaemia, occasional fever are the common manifestation of the disease. 
Extra articular manifestations are Rheumatoid nodules, lymph 
adenopathy, Spleenomegaly, Rheumatoid vasculitis, ophthalmic 
manifestations include scleritis, kerato-conjunctivitis and pleuritis, 
fibrous alveolitis. 
 
The study on Uthera Vatha Suronitham (Rheumatoid Arthritis) was 
with trial drugs. 
1. ‘Nkfehjp nkOF” (Meganathee Mezhugu) 130 m.g. two 
times per day with palm jaggery after meals internally. 
2. ’Kf;$l;L vz;nza;” (Mukkuttu Ennai) externally.  
 
Twenty cases of both sexes, and of various age groups were chosen 
and the study was carried out. 
 85% of the patients belonged to Pitha kaalam.  
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35% of the cases were seemed to develop the disease during Kaar 
kaalam (Aavani-Purattasi), 35% were noted in Koothir Kaalam (Ippasi-
Kaarthikai) and 25% were seen on Muthuvenil Kaalam (Aani – Aadi). 
 All the cases came from Marutha nilam. 75% of cases belonged to 
poor class families. Considering aetiology five percent of the cases had a 
positive family history. 
 80% of the cases had a gradual onset of disease. All the cases had 
joint pain, swelling, morning stiffness. 70% of the cases had restricted 
movements.  75% of the cases had initial involvement of joints of the 
upper limb. 
 In all the cases proximal interphalangeal joints and meta 
carpophalangeal joints were involved. Five percent of the cases had 
deformities in their interphanlangeal, metacarpophalangeal joints, wrist 
joint and elbow joint. 
 Regarding uyir thathukkal, viyanan and was were affected in 100% 
of the cases abanan was affected in 50% of cases samanan was affected in 
75% of cases.  Anala pitham was affected in 75% of the cases.  In 60% of 
the cases Ranjakam was affected and in 75% of the cases Sathaka pitham 
was affected. And Santhigam were affected all  the cases, Kilethagam 
was affected in 75% of cases. 
 Saaram was affected in all the cases. Senneer was affected in 60% 
of the cases.  Kozhuppu thathu and Enbu thathu were affected in 90% of 
cases. 
 Regarding Enn vagai thervugal, sparism. Naadi were affected in 
all the cases. Neerkuri was found straw in colour. Neikuri indicated that 
that spreads like Salladaik kan  in 30% of cases. 
Malam was affected in 50% of cases. 
35% of the cases had moderate restriction but with an ability to 
perform normal activities. 
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R.A. factor was positive in ten cases. 60% of the cases showed a 
decrease in haemoglobin percentage and raised E.S.R. level 
 The trial medicines were given to 20 Cases of Uthera Vatha 
Suronitham. 
 The internal drug was Meganathee Mezhugu (Nkfehjp nkOF) in 
the dose of 130 m.g. twice a day with palm jaggery after food. 
 The external drug was Mukkuttu Ennai (Kf;$l;L vz;nza;) which 
was applied externally to the affected joints. 
 Lemon soaked in Gingelly oil fomentation was given after the 
application of external drug. 
 All the patients were advised to follow the balanced dietary habit. 
 All the patients were also advised to follow the preventive 
measures like avoiding exposure to cold weather and advised to take bath 
in warm water. 
 The observation made during this study, showed that the trial 
medicines were clinically effective in reducing pain and swelling and 
increasing the range of movements.  The fomentation method is useful in 
reducing swelling and enhancing the flexibililty of joints. 
 The potency of the drugs were studied by Pharmacological and 
Biochemical analysis. 
 The drug Meganathee Mezhugu contains Calcium, Chloride, 
Ferrousiron, Unsaturated Compounds and Amino acids. 
 It shows that the drug Meganathee Mezhugu has 
significant Analgesic actions 
significant Acute anti  inflammatory action 
significant Chronic anti inflammatory action 
good  anti pyretic action. 
 The drug Mukkuttu Ennai has significant Acute anti inflammatory 
action. 
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CONCLUSION 
 
In this study, results were found to be moderate relief of signs and 
symptoms in Uthera Vatha Suronitham. 
In early diagnosed cases, it shows better results in prevention of 
disabilities and deformities of Rheumatoid Arthritis. 
With proper dosage no adverse effects were noticed during the 
treatment period. 
The medicine Meganathee Mezhugu can be used upto 5 years and 
Mukkuttu Ennai upto one year.   So they can be stored and used.   
The trial medicine has acute and chronic anti inflammatory, 
analgesic and antipyretic actions.  
The fomentation method with Lemon soaked in Gingelly oil is 
simple, easy available  and effective treatment in Uthera Vatha 
Suronitham. 
So it is concluded that the treatment with Meganathee Mezhugu 
(Nkfehjp nkOF) and Mukkuttu Ennai (Kf;$l;L vz;nza;) can be 
included as the supportive medicines in early stages of Uthera Vatha 
Suronitham. 
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PREPARATION AND PROPERTIES OF TRIAL DRUGS 
 
cs; kUe;J: 
Nkfehjp nkOF 
 
NrUk; ruf;FfSk;> msTfSk;: 
 
Rj;jpj;j g+uk;    - ½ gyk; 
Rj;jpj;j ,urn re;J}uk;  - ½ gyk; 
Xkk;     - 8 gyk; 
 
Rj;jp Kiwfs;: 
 
G+uk;  (HYDRARGYRUM SUBCHLORIDE) 
 
 xU gyk; ,urfw;G+uj;jpw;F fhy; gyk; fk;khWntw;wpiy> fhy;gyk; kpsF 
,uz;ilAk; rpwpJ ePh; tpl;L miuj;j fw;fj;ij xU gbePhpy; fye;J G+uj;ij 
rPiyapy; Kbe;J Jyhae;jpukhf ePhpy; mkpOk; gbnra;J rpW jPaha; vhpf;f 
Ntz;Lk;.  ePh; Kf;fhy; gq;F Rz;ba gpwF g+uj;ij vLj;J ePh; tpl;Lf; fOtp> 
ntapypy; cyh;j;jp vLf;fr; Rj;jpahFk;. 
 
,ur nre;J}uk; (RED SULPHIDE OF MERCURY) 
 vYkpr;rk; gor;rhw;wpy; 24 kzp Neuk; Cw itj;J fOtp cyh;j;jp vLf;f 
Rj;jpahFk;. 
 
Xkk; 
 Xkj;jpy; Jk;G J}rpfs; VJkpd;wp Rj;jk; nra;J vLj;J> ePhpy; eidj;J> 
tbfl;b Jzpapy; gug;gp> epoypy; cyh;j;jp vLj;J gpd;dh; ,sk; tWg;ghf 
tWj;J vLj;Jf; nfhs;sg;gl;lJ. 
107 
 
 
nra;Kiw: 
 
 ,urfw;G+uj;ij fy;tj;jpypl;L kpDkpDg;G ,y;yhky; MFk; tiu (3 
kzp Neuk;) miuj;Jf; nfhs;sg;gl;lJ. 
 ,ur nre;J}uj;ij fy;tj;jpypl;L 6 kzp Neuk; miuj;Jf; 
nfhs;sg;gl;lJ. 
 Xkj;ij ed;whf ,bj;J> gpd;dh; rpwpJ rpwpjhf fy;tj;jpypl;L nkOF 
Nghy; MFk; tiu miuj;Jf; nfhs;sg;gl;lJ. 
 gpd;dh; miuj;J itj;lJs;s ,urfw;G+uk;> ,urn re;J}uk; ,uz;ilAk;  
Nrh;j;J 1 kzp Neuk; ed;whf cwthFk; gb miuj;Jf; nfhs;sg;gl;lJ. 
 ,j;Jld; miuj;J itj;Js;s Xkj;ij rpwpJ rpwpjhf Nrh;j;J 
miujj;Jf; nfhz;Nl vy;yhtw;iwAk; xd;whf;fp> 6 kzpNeuk; (2rhkk;) 
ed;whf miuj;Jf; nfhs;sg;gl;lJ. 
 miuj;j nkOfpid fy;tj;jpypUe;J topj;njLj;J Rj;jkhd fz;zhb 
ghl;bypy; Nrfhpj;Jf; nfhs;sg;gl;lJ. 
msT: 
 kpsfsT (130 kpy;yp fpuhk;) 
mDghdk;:  
 gidnty;yk; 
jPUk; Neha;fs;: 
 Njftyp> iffhy;gpbg;G> Fj;jy;> Filr;ry;> typ> fpue;jp> Gz; Kjypa 
Neha;fs; jPUk;. 
MjhuE}y;: 
 ek; ehl;L itj;jpak; (gf;fk; - 361) 
njhFg;ghrphpah; : tPug;ngUkhs; gps;is mth;fs; 
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PROPERTIES OF INTERNAL TRIAL DURG 
G+uk;  (HYDRARGYRUM SUBCHLORIDE): 
 Rit: cg;G> fhh;g;G  tPhpak;: ntg;gk;   gphpT: fhh;g;G 
Fzk;:  
 ‘,ilthj #iy nahp#iy Fd;ke; 
 njhilthio thjkhQ; Nrhzp - apilahNjh 
 nthf;Fur fh;g;G+u nkhd;Nw asnthLey; 
 ,f;F nty;yj; NjOeh sP.” 
 
 ,Lg;igg; gw;wpa #iy> Mq;fhq;F vhpr;riyj; jUfpd;w #iy> thjFd;kk;> 
njhilthio> thjuj;j Neha; Kjypad jPUk;. 
 
,ur nre;J}uk; (RED SULPHIDE OF MERCURY) 
 ,ur nre;J}uj;jpDila Rit> tPhpak;> tpghfk;> Fzk;> nra;if 
Kjypad rw;Nwwf;Fiwa ,ypq;fj;ij xf;Fk;. 
 
 vdNt> ,J ntg;g tPhpaj;ijAk;> cly;Njw;wp nra;ifAk; cilaJ. 
 
 ‘NgjpRuQ; re;ep ngUtpuz ePnuhLj 
 fhjfbfhrq; fug;ghd;Gz; - Nzhj 
 TUtpypq;f rq;fjkh A+Wfl;b Ak;Nghq;  
 FUtpypq;f rq;fkj;ijf; nfhs;.” 
 
 ‘Mjp apujTUf; fhjyhw;rhjpjypq;f 
 Nkhjp ypujFz Kw;Wlypw; - wPJGhp 
 Fl;lq; fpue;jp nfhLQ;#iy thjKj  
 Yl;lq;F Neha;fis Nahl; Lk;.” 
 
Xkk; (Carum coptium) 
 Rit : fhh;g;G jd;ik : ntg;gk; gphpT : fhh;g;G 
‘rPjRuq; fhrQ; nrhpahke; jk;nghUky; 
Ngjpapiur; ry;fLg;G Nguhkk; -XjpUky; 
gy;nyhLgy; %yk; gfkpitNeh nad;nrANkh? 
nrhy;nyhLNghk; Xknkdr; nrhy;.”  - mfj;jpah; Fzthflk;. 
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jPUk; Neha;fs;: 
 nrhpahik> Flypiur;ry;> thA ePq;Fk;. 
 
‘. . .  Nfhit aikr;irau rhs;tpf;Fk; 
Xl;Ltpf;Fk; je;jphpia Az;ikaha;j; - jhl;Bfk; 
G+Zk; gpukruk; Nghyg; gpzpfSf;Ff;  
fhZ krkjh fk;”. 
- Njiuah; fhg;gpak;. 
mrkjhfk; vDk; Xkk; mlq;fpa thjj;ij jd;dpiyailar; nra;Ak;.  
gpj;jj;ij muR epiyf;F NkNyhq;Ftpf;Fk;.  Nrj;Jkj;ij ePf;Fk;.  
nkd;ikahd; typikAila gpukhj;jpuk; Nghy; gpzpfis jPh;f;Fk; kUe;jhFk;. 
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ntsp kUe;J: 
Kf;$l;L vz;nza; 
 
NrUk; ruf;FfSk;> msTfSk;: 
FWe;njhl;b %yk;   - ¼ Jyhk; (875fpuhk;) 
Mtpd; nea;    - ½ gb (650 kp.yp.) 
Vuz;lj;njz;nza;  - ½ gb (650 kp.yp.) 
ey;nyz;nza;   - ½ gb (650 kp.yp.) 
nghhpfhuk;    - 10 foQ;R (51 fpuhk;) 
Ntk;ghlk;gl;il   - 10 foQ;R (51 fpuhk;) 
kQ;rs; nkOF   - 10 foQ;R (51 fpuhk;) 
 
(Fwpg;G:  1 Jyhk; = 3500 fpuhk; : 1 gb = 1300 kp.yp. : 1 foQ;R = 5.1 fpuhk;) 
 
nra;Kiw: 
 FWe;njhl;b %yj;ij ,bj;J > J}zp (21.5 ypl;lh;) ePhpl;L fha;r;rp 
vl;nlhd;whf tw;w nra;J> mNjhL Mtpd; nea;> Vuz;lj;njz;nza;> 
ey;nyz;nza; Mfpa nea;fis Nrh;j;J fha;r;rp nfhjpf;Fk; NghJ 
nghhpfhuk;> Ntk;ghlk;gl;il> kQ;rs; nkOF  Nrh;j;J rpW jPahf vhpj;J nkOF 
gjj;jpy; tbj;J gjg;gLj;jg; gl;lJ. 
 
jPUk; Neha;fs;: 
 clypy; G+r thjNeha;fs; FzkhFk;.  kuj;Jg; Nghjy; khWk;.  euk;G 
tpirnfhs;sy;> tpuzq;fs; khWk;.  fhy; th;kq;fs; FzkhFk;. 
Mjhu E}y;: 
 th;k kUe;J nra;Kiwfs; (gf;fk; - 373) 
  E}yhrphpah;: kU. j. fz;zd; uhrhuhk;> B.S.M.S. 
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PROPERTIES OF EXTERNAL DRUG 
FWe;njhl;b %yk; (rpw;whKl;b Nth;) – Sida cordifolia 
 Rit : Jth;g;G jd;ik : jl;gk;   gphpT : ,dpg;G 
 
‘mj;jp RuKjy;mde;jRuk; gpj;jKk;Nghk; 
nkj;j tpopf; nfhspahk; tPWjap - yj;jpw;fhk; 
ew;wh kiuj;jpUT ehL nkhopw;wpUNt! 
rpw;whKl; bj;Jiur; nrg;G.” 
      - mfj;jpah; Fzthflk;. 
vYk;G Ruk;> moy; Neha; ,it ePq;fp fz;Zf;F xspAz;lhFk;.  ,J 
ijyq;fspy; NrUk;. 
 
Mtpd; nea; (gR nea;)  -  Ghee 
 ‘jhfKo iyRl;fk; the;jpgpj;jk; thAgpu  
 Nkfk; tapw;nwhpT tpf;fyoy; - khfhrq; 
 Fd;kk; twl;rp Flw;Gul;l y];jp Rl;fQ; 
 nrhd;%yk; Nghf;Fepiwj; Jg;G.” 
jPUk; Neha;fs;: 
 gRtpd; nea;ahy; thjtplk;> twl;rp ,tw;iw ePf;Fk;. 
Ghee is much esteemed as an application over wounds, 
inflammatory swellings and blistered surfaces.  Ghee is also used as in 
the preparations of medicated oils and as an ointment base. 
Vuz;lj;njz;nza; (Mkzf;nfz;nza;) - Ricinus communis 
(Castor Oil) 
Rit : ifg;G jd;ik : ntg;gk;   gphpT : fhh;g;G 
Fzk; : 
‘Nauz;ljJnea; nad;gJ lw; nfhL 
rPuz;lj;jzp nra;jpL Nk.” 
- Njuh; fhg;gpak;. 
Mkzf;F vz;;nza; clw;F td;ikf; nfhLf;ff; $baJ. 
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 ‘Mkzf; nfz;nza;  jd;id azpepy kwpaf; Nfz;kpd; G+kzr; 
re;JNjhWk; nghUe;jpa thjk; NghFk;” 
- gjhh;j;j Fz rpe;jhkzp 
jPUk; Neha;fs; : 
 - re;Jfs;; NjhWk; Njhd;Wk; thjj;ij Nghf;Fk;. 
- Castor oil is much praised for its efficacy in Chronic Articular  
Rheumatism in which it is used in various combination. 
  
ey;nyz;nza; (vs;;nea;) - Sesamum indicum 
Rit : ,dpg;G  jd;ik : ntg;gk;   gphpT : ,dpg;G 
Fzk; : 
 “nrg;ghpa thjgpj;jj; jPikafYk;” 
- gjhh;j;j Fz rpe;jhkzp 
‘Gj;jp eadf;Fsph;r;rp G+hpg;G nka;g;GsfQ; 
 rj;Jtq;  fe;jp jdpapsik - nkj;jTz;lhq; 
 fz;Nzha; nrtpNeha; fghytoy; fhrNeha; 
 Gz;Nzha;Ngh nkz;nza;ahw; Nghw;W“ 
- mfj;jpah; Fzthflk;. 
jPUk; Neha;fs; : 
 cly; td;ik jUk;. thj gpj;j Neha;fs; jPUk;. 
 
 
nghhpfhuk; (ntq;fhuk;) - BORAX 
Rit : ,dpg;G> Jth;g;G jd;ik : ntg;gk; gphpT : ,dpg;G 
‘nrhwpGil naz;Fd;k eikNrhhp ahrk; 
gwpfpufzp fy;Ydk; gd;Ndha;- newpiaj; 
jlq;fzq;f gq;fpUkp rh;g;gtplQ; re;ep 
aplq;fzq;f yf;fpw;Ngh nkz;.” 
 
jPUk; Neha;fs; : 
 vz;tif Fd;kk;> gq;Fthjk;> re;epghjk; jPUk;. 
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Ntk;ghlk;gl;il (Red Creeper) - Ventilago maderaspatana  
nra;;iffs;:    
  Bitter, Astringent, Thermogenic, Digestive, Carminative, 
Stomachic, Stimulant and Tonic. 
kQ;rs; nkOF  -  WAX 
‘miwgf;f thj kijg;iga %ij 
Fiwtpe;jp jo;Neha; Njs;$dp - fiwiag;  
GOnfLf;f tq;fKW Gz;zpbg;Gz; Bg;Gz; 
nkOnfLf;f thq;fY nka;”. 
jPUk; Neha;fs;: 
 ghhprthA> tPf;fk;> fgNeha;> thjNjhlk; jPUk;. 
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BIO - CHEMICAL ANALYSIS OF   
MEGANATHEE MEZHUGU 
Preparation of the extract: 
5gms of MEGANATHEE MEZHUGU was weighed accurately 
and placed in a 250ml clean beaker. Then 50 ml distilled water is added 
to it and dissolved well.  Then it was boiled well for about 10 minutes. It 
was cooled and filtered in a 100 ml volumetric flask and then it is made 
up to 100ml with distilled water. This fluid is taken for analysis. 
Qualitative analysis: 
S.No            Experiment Observation Inference 
1. TEST FOR CALCIUM 
2ml of the above prepared 
extract is taken in clean test 
tube. Add 2ml of 4% 
Ammonium oxalate solution 
is added to it. 
 
A white 
Precipitate  
is formed 
 
Indicates 
 the presence 
of calcium 
2. TEST FOR SULPHATE: 
2ml of the extract is added to 
5% barium chloride solution. 
No white 
Precipitate 
is formed 
Absence of 
Sulphate 
3. TEST FOR CHLORIDE: 
The extract is treated with 
silver nitrate solution 
White 
Precipitate  
is formed 
Indicates the 
presence of 
Chloride 
4. TEST FOR CARBONATE:
The substance is treated with 
concentrated HCL. 
No brisk 
Effervessence 
is formed 
Absence of 
Carbonate 
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5. TEST FOR ZINC: 
The extract is added with 
Potassium ferro cyanide 
solution. 
No white 
precipitate is 
formed 
Absence of 
Zinc 
6. TEST FOR IRON FERRIC 
FERRIC: the extract is 
treated with glacial acetic 
acid and potassium Ferro 
cyanide. 
 
No blue 
Colour is 
formed 
Absence of 
ferric Iron. 
7. TEST OF IRON 
FERROUS: 
The extract is treated with 
concentrated Nitric acid and 
ammomuin thio cyanate: 
 
Blood 
Red colour 
is formed 
Indicates the 
presence of 
Ferrous Iron 
8. TEST FOR PHOSPHATE: 
The extract is treated with 
ammonium Molybdate and 
concentrated nitric acid 
No yellow 
Precipitate 
is formed 
Absence of 
phosphate 
9. TEST FOR ALBUMIN: 
The extract is treated with 
Esbach’s reagent 
No yellow 
Precipitate 
is formed 
Absence of 
Albumin 
 
10. TEST FOR TANNIC 
ACID: 
The extract is treated with 
ferric chloride reagent 
No blue black 
Precipitate is 
formed 
Absence of 
Tannic acid 
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11. TEST FOR 
UNSATURATION: 
Potassium permanganate 
solution is added 
to the extract 
It gets 
decolourised 
Indicates 
the presence 
of 
unsaturated 
compound 
12. TEST FOR THE 
REDUCING SUGAR: 
5ml of Benedict’s qualitative 
solution is taken in a test tube 
and allowed to boil for 2 mts 
and added 8-10 drops of the 
extract and again boil it for 2 
mts. 
 
No Colour 
change 
occurs 
 
 
Absence 
of reducing 
Sugar  
 
 
13. TEST FOR AMINO ACID: 
One or two drops of the 
extract is placed on a filter 
paper and dried it well after 
drying 1% Ninhydrin is 
sprayed over the same and 
dried it well. 
 
 
Violet 
colour is 
formed 
 
 
Indicates the 
presence of 
Amino acid 
 
Inference:  
The given sample of Meganathee Mezhugu contains Calcium, 
Chloride, Ferrous iron, Unsaturated Compounds and Amino acids. 
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ANALGESIC STUDY OF MEGANATHEE MEZHUGU 
Aim 
To study the effects of analgesic action on Albino rats by Tail - 
Flick method. 
Instruments 
Dolonometer (or) Analegesic using heated nicrome wire a source 
of stimulus. 
Procedure 
6 albino rats were selected on either sex and divided into 3 groups. 
Each group having 2 rats were weighting between 100 – 150 gm. The rat 
is holded on the instrument. So that the tail lies over the nichrome wire on 
analgesiometer without touching it. To heat the nicrome wire by 
switching it on and at the same  time starting a stop watch. The time takes 
for the rat to flick the tail was noted. This is the reaction time. This was 
noted for each rat and the average was calculated. This is kept as control 
volume. 
Paracetamol was administered at a dose of 20 mg / 100 mg of body 
weight orally to the second group of rats, the reaction time was noted 
after the administration of ½ hr. and one hour and the average is 
calculated. The test does was given for the third group of rats. 
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The result of test drug is compared with the standard as well as 
control group 
S.No. Group 
Dose-100 gm 
of body weight
Initial 
Readings  in 
second 
After 
½ hr 
in 
second 
After 
1 hr 
in 
second
1. Control Water – 2ml 
3 Secs 
 
3 Secs 
2.5 
Secs 
2. 
Standard 
 
Paracetamol – 
20 mg 
3 Secs 
7.5 
Secs 
 
8 Secs 
3. 
Meganathee 
Mezhugu 
Meganathee 
Mezhugu –  
20 mg 
 
3 Secs 5 Secs 6 Secs 
 
Inference: 
From the above tabulation it is noted that Meganathee Mezhugu 
has Significant Analgesic action. 
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ANTI-PYRETIC STUDY ON MEGANATHEE MEZHUGU 
Aim 
 To study the anti-pyretic activity of the Meganathee Mezhugu 
Procedure 
 Three groups of healthy albino rats were taken, each weigh about 
100-200gm and divided into three groups, each group consists of 2 rats. 
All the rats were made hyperthermic by subcutaneous injection of 12% 
suspension of Yeast at a dose of 100ml/100mg body weight. 
 10 hrs later one group of rats were given the test drug Meganathee 
Mezhugu at a dose of 1 ml at a dose of 20 mg/100 gm of body weight. 
The other group received distilled water at a dose of 1 ml/100 gm of body 
weight and kept as control. The last group was given Paracetamol at a 
dose of 100 mg/ 100 gm body weight and kept as standard. 
 The mean rectal temperature for 3 groups was recorded at 0 hr, ½ 
hr, 3 hr, 4 ½ hrs after the drug administration. The difference in mean 
temperature between the 3 groups were noted and compared. 
Group 
Dose volume 
orally/100gm 
bw 
Mean temperature 
Initial ½ hr 3 hr 4 ½ hr 
Control  1 ml 36.5 36.5 37.0 38 
Paracetamol 20 mg 37.5 37.0 36.5 34.5 
Meganathee 
Mezhugu 
20mg 37.0 36.0 36 35.5 
 
Inference - The test drug Meganathee Mezhugu  has good Anti pyretic 
action. 
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ACUTE ANTI-INFLAMMATORY ACTIVITY IN RATS 
BY HIND-PAW METHOD 
Aim: 
To demonstrate the acute anti-inflammatory activity of Meganathee 
Mezhugu   in albino rats by Hind-paw method. 
Procedure: 
 Nine Albino rats weighing 100-150gm were taken and divided into 
three groups and each group consisting three rats. 
 First group was kept as control and received water.  Second group 
received Ibuprofen at a dose of 20mg/100gm-body weight.  Third group 
animals received Meganathee mezhugh  suspension at a dose of 
200mg/100gm-body weight. 
 Before administration of drugs, the Hind-paw volume of all the rats 
were measured.  This was done by dipping the Hind-paw upto the tibio-tarsal 
junction in mercury plethysmograph.  Soon after the measurement at the drugs 
were administered.  One hour after the administration of drugs a sub-cutaneous 
injection of 0.1ml of 1%/W/V of carrageenin in water was made into planter 
surface of both the Hind-paw of each rat. 
Three hours after carrageenin injection, the Hind-paw volume was 
measured once again.  Difference between the initial and final value were 
noted and compared. 
This method is more suitable method for studying anti-inflammatory 
activity in acute inflammation. 
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The effect of Meganathee Mezhugu in acute anti-inflammatory activities. 
 
Group 
Dose volume 
orally 
Initial 
reading 
Final 
reading 
Mean 
difference 
Percentage 
Inflammation 
Percentage 
Inhibition 
Control Water 2 ml 0.8 1.5 0.7 100 - 
Standard 
Ibuprofen 
20mg/100gm 
0.7 0.95 0.25 35.7 64.3 
Test 
drug 
20mg/100gm 0.45 0.8 0.35 41.17 58.8 
 
Result: 
 The drug Meganathee Mezhugu has Significant acute – anti 
inflammatory action. 
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CHRONIC ANTI-INFLAMMATORY STUDY BY COTTON-
PELLETS GRANULOMA METHOD   
Aim: 
 To study the chronic anti-inflammatory activity of the drug in albino rats 
by cotton pellets implantation (granuloma) method. 
Procedure: 
 Cotton pellets each weighing long was prepared and sterilized in an 
autoclave for about one hour under 15 lbs atmosphere pressure.  Nine Albino 
rats weighing between 100-200gm were selected and were divided into 3 
groups.  Each rat was anaesthetized with ether and cotton pellets were 
implanted subcutaneously in the groin, two in each side. 
 From the day of implantation, one group of animals received 
Meganathee Mezhugu  at a dose of 20mg/100gm of body weight.  
 On the eighth day the rats were sacrificed and the pellets were removed 
weighed.  Then they were put in an incubator at 60ºC-80ºC and then weighed. 
The concordant weight was noted for all groups and compared. 
The effect of Meganathee Mezhugu in chronic anti inflammatory study. 
Group Dose given orally 
 
Pellet 
Weight 
Pellet weight 
of the 
Granuloma of 
drugs 
Percentage 
inflammation 
Percentage 
inhibition 
Control Water 2ml 10 mg 250 100 - 
Standard 
Ibuprofen 
20mg/100gm 
body weight 
10 mg 
 
55 
 
22 
 
78 
Test 
drug 
20mg/100gm 
body weight 
10 mg 99 40 60 
 
Inference : The drug show Significant  chronic – anti inflammatory action. 
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ACUTE ANTI – INFLAMMATORY STUDY ON 
MUKKUTTU ENNAI 
(EXTERNAL USE) 
By Hind – Paw method in Albino Rats 
Aim 
 To study the acute antiinflammatory activity of the test drug  
Mukkuttu Ennai. 
Procedure 
 Six healthy albino rats weighing 100 -150 gm, were taken and 
divided into two groups, each consisting of 3 rats. 
 First group was kept as control by giving distilled water 2 ml/ 100 
gms of body weight. The second group was kept as test group. 
 Before application of test drug, the hind – paw volume of all rats 
were measured. This was done by dipping the hind – paw (upto tibiotrasal 
junction) into a mercury plethysmography. While dipping the hind paw, 
by pulling the syringe piston, the level of mercury in the ventre small tube 
was made to coincide with red marking and reading was noted from the 
plethysmograph. 
 One hour later, a sub – cutaneous injection of 0.1 ml of 1% (W/V) 
carrageenin in water was made into plantar surface of both hind – paw of 
each rat. To the second test group Mukkuttu Ennai  was topically applied 
for three times over the inflamed surface in a thin layer with 30 minutes 
gap. To the other groups no drug was applied over the inflamed surface. 
 One and half hour after injection. The hind – paw volume was 
measured once again. The difference between the initial and final volume 
would show the amount of inflammation. Taking the volume in the 
control groups as 100% of inflammation, anti – inflammatory effect of 
the test group is calculated. 
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Effect of Mukkuttu Ennai.:  
S.No. Group 
Dose/100gm 
Of body 
weight 
 
Initial 
Reading 
Final 
Reading 
Mean 
Difference 
Percentage of 
Inflammation 
Percentage 
of 
inhibition 
1. Control 
Water – 
2 ml 
0.8 1.5 0.7 100 - 
2. Standard 2 ml 0.7 0.95 0.25 35.7 64.3 
3. 
Test drug 
Mukkuttu 
Ennai. 
 
External 0.87 1.15 0.28 25.8 67.1 
 
Inference: 
 It is observed that Mukkuttu Ennai has Significant Acute Anti- 
inflammatory action.  
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PROFORMA OF CASE SHEET 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI. TRIRUNELVELI – 627 002 
Branch – III Sirappu Maruthuvam 
Dissertation done by: 
I.P. No :    Occupation  : 
Bed No :    Income  : 
Ward  :    Nationality  : 
Name  :    Religion  : 
Age  :    Date of Admission : 
  :    Date of Discharge : 
Sex  :    Diagnosis  : 
      Result  : 
      Medical Officer : 
Permanent Address : 
 
Complaints and duration : 
 
History of Present illness : 
 
History of Previous illness : 
 
Personal history including habits: 
 
Family History  : 
 
Socio-economic Status : 
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GENERAL CONDITIONS ON EXAMINATION 
 
1. Consciousness   : 
 
2. General appearance  : 
 
3. Stature    : 
 
4. Nourishment   : 
 
5.Skin Changes   : 
 
6. Face    : 
 
7. Pallor    : 
 
8. Jaundice    : 
 
9. Cyanosis    : 
 
10. Clubbing   : 
 
11. Lymphadenopathy  : 
 
12. Abdominal Distension : 
 
13. Jugular Venous Pulsation : 
 
14. Engorged Veins  : 
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15. Koilonychia   : 
 
16. Pedal oedema   : 
 
17. Generalised Oedema  : 
 
18. Temperature   : 
 
19. Pulse    : 
 
  Rate   : 
  Rhythm  : 
  Volume  : 
  Character  : 
  peripheral pulses : 
  Pulses paradoxus : 
     
20. Respiratory Rate  : /min 
21. Heart Rate   : 
22. Blood pressure   : 
 Right Left 
Upper limb   
 
23. Miscellaneous   : 
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rpj;j Kiw NjHT  
1.  epyk; 
 FwpQ;rp 
 Ky;iy 
 kUjk; 
 nea;jy; 
 ghiy 
2. gUt fhyk; 
 fhH fhyk;   (Mtzp - Gul;lhrp) 
 $jpH fhyk;  (Ig;grp - fhHj;jpif) 
 Kd;gdp   ( khHfop - ij 
 gpd;gdp   ( khrp- gq;Fdp) 
 ,sNtdpy;  ( rpj;jpiu - itfhrp) 
 KJNtdpy;  ( Mdp - Mb) 
3. ahf;if (cly;) 
 thjk; 
 gpj;jk; 
 fgk; 
 fyg;G 
4. Fzk; 
 rj;Jtk; 
 ,uhrjk; 
 jhkrk; 
5. nghwp Gyd;fs; 
 nka; - CW 
 tha; - Rit 
 fz; - xsp 
 %f;F - ehw;wk; 
 nrtp - xyp  
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6. fd;Nke;jphpak; 
 if - jhdk; 
 fhy; - fkdk; 
 tha; - trdk; 
 vUtha; - tprHf;fk; 
 fUtha; - Mde;jk; 
7. cl;fhak; 
 Njhs; nghUj;J 
 Gak; 
 Koq;if nghUj;J 
 rak; 
 iff;FsR 
 fugk; 
 mq;Fyp 
 mq;Frk; 
8. mjf;fhak; 
 ,Lg;G nghUj;J 
 njhil 
 Koq;fhy; nghUj;J 
 Kd;fhy; 
 Fjpq;fhy; 
 fugk; 
 mq;Fyp 
 tk;rp 
9. Kk;kyk; 
 kyk;    - 
 %j;jpuk;   - 
 tpaHit   - 
10. gpw cWg;Gfspd; epiy 
 ,Ujak;   - 
 Gg;Grk;   - 
 ,iug;ig   - 
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 fy;yPuy;   - 
 kz;zPuy;   - 
 rpWFly;   - 
 ngUq;Fly;   - 
 rpWePufk;   - 
 %is  - 
 fUg;ig   - 
11. capH jhJf;fs; 
(m) thjk;   - 
 gpuhzd;   - 
 mghdd;   - 
 tpahdd;   - 
 cjhdd;   - 
 rkhdd;   - 
 ehfd;   - 
 $Hkd;   - 
 fpUfud;   - 
 Njtjj;jd;   -  
 jdQ;nrad;  - 
(M) gpj;jk; 
 mdw; gpj;jk;  - 
 ,uQ;rf gpj;jk;  - 
 rhjf gpj;jk;  - 
 MNyhrf gpj;jk;  - 
 gpuhrf gpj;jk;  - 
(,) fgk; 
 mtyk;gfk;   - 
 fpNyjfk;   - 
 Nghjfk;   - 
 jw;gfk;   - 
 re;jpfk;   - 
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12. cly; jhJf;fs; 
 rhuk;    - 
 nre;ePH   - 
 Cz;    - 
 nfhOg;G   - 
 vd;G    - 
 %is   - 
 Rf;fpyk;/RNuhzpjk; - 
13. vz; tifj;NjHTfs;  
 ehb    - 
 ];ghprk;   - 
 eh    - 
 epwk;    - 
 nkhop    - 
 tpop    - 
kyk; 
 rpWePh; 
1. ePh;f;Fwp 
epwk;  - 
  kzk;  - 
vil  - 
  ,Wfy; - 
  ,sfy; - 
2. nea;f;Fwp 
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LABORATORY INVESTIGATION 
1. BLOOD: 
 TC : cells/ cu. mm 
 DC :   P % L % E % M % 
 ESR : 
   ½ hour : mm 
    I hour : mm 
Hb   : 
 Blood Sugar  : 
 Blood Urea  : 
 Serum Cholesterol : 
 Uric Acid  : 
 VDRL  : 
2. URINE 
 Albumin  : 
 Sugar   : 
 Deposits  : 
3. MOTION 
 Ova   :        Cyst   : 
4. IMMUNOLOGICAL : 
 RA Factor  : 
5.RADIOGRAPHIC FINDINGS : 
6. SEROLOGICAL TEST FOR SYPHILIS : 
7. SYNOVIAL FLUID ANALYSIS : 
8. ARTHROGRAPHY : 
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 LOCOMOTOR SYSTEM 
INSPECTION 
Overlying Skin: 
 Colour   : 
 Scars and ulcers  : 
 Periarticular swelling : 
Bones: 
 Deformity   : 
 Unusual posture  : 
 Muscle changes  : 
 Symmetrical distribution : 
 joint movements  : 
 Gait    : 
Palpation: 
 Skin Temperature  : 
 Soft Tissues   : 
 Bony Enlargement  : 
 Crepitus   : 
 Sub-cutaneous nodules : 
 Rheumatoid vasculitic lesion : 
 Lymphadenopthy  : 
 pitting Iedema  : 
Range of Movements  : 
Examination of individual joints: 
 Cervical Spine   : 
 Thoracic Spine  : 
 Lumbar Spine   : 
 Sacro-illac Joint  : 
 Shoulder Joint   : 
 Elbow Joint   : 
 Wrist Joint   : 
 Metacarpophalangeal joint  : 
 Interphalangeal Joint  : 
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 Hip Joint   : 
 Knee joint   : 
 Metatarso phalangeal Joint: 
Examination of individual joints (Affected Joints) 
Measurement (in cm) : 
Before and After Treatment: 
Affected Joints RIGHT LEFT 
BEFORE AFTER BEFORE AFTER 
Knee Joint 
Ankle Joint 
Wrist Joint 
Elbow joint 
Index finger 
Middle finger 
Ring finger 
Little finger 
    
 
EXAMINATION OF OTHER SYSTEMS: 
1. Respiratory system  : 
2. Cardio Vascular system : 
3. Gastro Intestinal system : 
4. Central Nervous system :  
 
DAILY PROGRESS 
 
DATE SYMPTOMS DRUG 
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GOVERNMENT SIDDHA MEDICAL COLLEGE HOSPITAL, 
POST GRADUATE DEPARTMENT, 
PALAYAMKOTTAI, TIRUNELVELI-627 002 
BRANCH – III SIRAPPU MARUTHUVAM. 
ADMISSION-DISCHARGE SHEET FOR “Uthera Vatha Suronitham” 
 
IP No   :    Occupation : 
Bed No  :    Income : 
Ward   :    Nationality : 
Name   :    Religion : 
Age   :    Date of Admission : 
Sex   :    Date of Discharge : 
Permanent Address:    Diagnosis : 
       Result : 
Temporary Address:    Medical officer : 
CLINICAL PICTURES 
 
Sl.No. During Admission During Discharge 
  
 
 
 
 
 
 
 
 
PLACE: 
DATE:      Signature of Medical Officer. 
136 
 
 
BIBLOGRAPHY 
 
1.  Njhw;wf;fpuk Muha;r;rpAk; rpj;j kUj;Jt tuyhWk; -kU.f.R.cj;jkuhad;. 
2.  cly; jj;Jtk; - kU. G.K. NtZNfhghy;  
3.  Neha;ehly; Neha; Kjdhly; ghfk; I & II - kU. k. rz;KfNtY> H.P.I.M. 
4.  rpj;j kUj;Jthq;fr; RUf;fk; - kU. f.R. cj;jkuhad; 
5.  rpwg;G kUj;Jtk; - kU. Mh;. jpahfuhrd; LIM 
6.  rpj;j kUj;Jtk; - kU. e. Fg;Grhkp Kjypahh;> H.P.I.M. 
7.  Fzghlk; %ypif tFg;G - kU. KUNfr Kjypahh; 
8.  Fzghlk; jhJ rPt tFg;G  - kU. Mh;. jpahfuhrd; 
9.  Nehapy;yh newp - kU. Nfh. Jiuuhrd;> 
10.  A+fp itj;jpa rpe;jhkzp 800  
11.  ek; ehl;L itj;jpak; - Mrphpah; S. tPug;ngUkhs; gps;is 
12.  th;k kUe;J nra;Kiwfs; - kU.j. fz;zd; uhrhuhk;> B.S.M.S. 
13.  gjhh;j;j Fzrpe;jhkzp 
14.  guuhrNrfuk; - thjNuhf epjhdk; 
15.  ruNge;jpuh; itj;jpa Kiwfs; - thjNuhf rpfpr;ir 
16. mfj;jpah; Fzthflk; 
17. Nahf rhjdh - jpU. rP. nt. ntq;fNlRtud;> M.Sc., M.Phil. 
18. Njiuah; thflk; 
19. Njiuah; fhg;gpak; 
20.  rpfpr;rh uj;d jPgk;. 
21. j. tp. rhk;grptk; gps;is jkpo; mfuhjp 
22.  Materia Medica – Dr. K.M. Nadkarani 
23. Gray’s Anatomy. 
24. Text book of physiology – Guyton. 
25.  Harrison’s principles of Internal medicine. 
26.  Stedman’s Medical Dictionary. 
27. Apley’s system of orthopedics and fractures. 
28.  Text book of orthopedics – Mercer’s. 
29. Orthopedics and Traumatology – G.S. Kulkarni 
30. Orthopaedics and Traumatology – Dr.M. Natarajan 
137 
 
 
31. Text book of preventive and social medicine 
32. The treatise of Indian Medicinal plants. 
33. Text book of medicine – Dr. K.V. Krishna dass 3rd edition 
34. Davidson’s principles and practice of medicine – 18th edition 
35. Text book of orthopedics – Dr. John Ebenezer. 
36. Short practice of surgery – Bailey and love 21st edition 
37.  Basic pathology – vinaykumar, S.cortran, Stanley L. Robbins 
38.  Oxford text book of medicine 
39.  Text book of medicine – P.C.Das 
40.  Physiology of Exercise – Daved R. Lamp 
41.  The priniciples of exercise, Students edition John V. Basmajian 
42.  Hutchinson’s clinicals methods – 20th edition 
43.  Anderson’s pathology 
44.  Robins pathologic basic of diseases 
45.  Primer on the Rheumatic diseases – 10th edition 
46. BMJ Journals of Update on Orthopaedics - 2008 
47. www.google.com 
48. www.rheumatoidarthritis.co.in 
49. www.arthritis.co.in 
50.  www.en.wikepedia.org 
 
2 1579 SAMSU 50/F 31.07.09 21.08.09 22 do 95 170 27 Negative
3 1719 RANI VIJAYA 42/F 14.08.09 12.10.09 60 do 109 130 14 Positive
4 1608 INDIRANI 52/F 07.08.09 20.08.09 14 do 145 195 30 Negative
5 1970 AVUDAYAMMAL 65/F 17.09.09 13.10.09 27 do 120 172 19 Positive
6 1816 SAROJA 54/F 27.08.09 12.09.09 16 do 75 158 22 Negative
7 2520 THIRUMALAI VADIVU 27/F 21.11.09 15.12.09 25 do 182 169 22 Negative
8 2630 JAYALAKSHMI 50/F 03.12.09 19.12.09 17 do 72 220 36 Positive
9 2431 RATHINAM 50/F 10.12.09 21.12.09 12 do 99 161 22 Negative
10 2671 KRISHNAMMAL 50/F 12.12.09 18.12.09 7 do 69 193 31 Positive
11 2603 SARASVATHI 40/F 16.12.09 26.12.09 11 do 84 173 27 Negative
12 1769 MURUGAN 24/M 21.08.09 09.09.09 20 do 91 120 48 Negative
13 1665 SARASWATHI 48/F 10.08.09 07.09.09 29 do 145 138 29 Positive
14 1694 PETCHIAMMAL 50/F 12.08.09 18.08.09 7 do 100 199 19 Negative
15 2400 MURUGAMMAL 52/F 04.11.09 13.11.09 10 do 128 198 34 Negative
16 2064 SELVI 38/F 29.09.09 07.11.09 39 do 140 180 23 Positive
17 1516 AVUDAYAMMAL 55/F 25.07.09 03.08.09 10 do 165 194 19 Negative
18 2004 PARVATHI 28/F 21.09.09 28.10.09 38 do 112 155 18 Positive
19 2202 GUNASUNDARI 52/F 19.10.09 02.12.09 45 do 129 163 16 Positive
20 2473 RAMALAKSHMI 42/F 14.11.09 09.12.09 26 do 83 211 25 Positive
Blood 
Sugar ( R ) 
mg%
Serum 
Cholesterol
mg%
Blood 
Urea    
mg%
Meganathee Mezhugu - 
130 mg and 
MukkukkuEnnai -30 ml
871344 162 1965 Positive
No.of 
days 
Treated 
Drugs Given
Investigation
RA FACTOR
1 LAKSHMI 55/F 04.07.09 06.09.09
List of Inpatients of PG-III Sirappu Maruthuvam Department
Given (1) Meganathee Mezhugu as Internal Medicine
    (2) Mukkuttu Ennai as External Medicine  
Haematological Investigations of Patients of Uthera Vatha Suronitham
S.No IP No Name Age Sex 
Date of 
Admission
Date of 
Discharge 
P% L% E% P% L% E% 1/2 hr 1 hr 1/2 hr 1 hr
1 1344 7900 8100 66 32 2 53 43 4 30 60 25 36 60% 65% NIL NIL
10-15
pus
 cells
NIL NIL few epi NIL NIL NIL NIL
2 1579 9400 9600 54 38 8 52 40 6 10 25 8 20 54% 60% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
3 1719 7400 8200 60 35 5 58 38 4 15 30 10 20 78% 74% NIL NIL few epi NIL NIL NIL NIL NIL NIL NIL
4 1608 9000 9200 58 40 2 60 38 2 8 20 6 14 68% 72% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
5 1970 8500 8600 56 39 5 53 42 4 35 50 30 40 70% 74% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
6 1816 9200 9300 56 40 4 58 40 2 7 14 5 10 71% 75% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
7 2520 8200 8900 52 40 8 49 48 3 5 11 3 7 72% 72% NIL NIL 1-2 epi NIL NIL NIL NIL NIL NIL NIL
8 2630 8900 9400 62 30 8 62 34 4 25 45 5 10 71% 72% NIL NIL 1-2 epi NIL NIL NIL NIL NIL NIL NIL
9 2431 8800 10400 56 40 2 64 34 2 40 70 30 65 64% 65% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
10 2671 7800 7900 52 44 4 53 43 4 15 30 7 14 72% 74% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
11 2603 8600 10200 56 38 6 59 34 4 25 47 15 30 72% 73% NIL NIL few epi NIL NIL NIL NIL NIL NIL NIL
12 1769 8500 9100 64 34 2 66 32 2 28 50 20 30 74% 75% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
13 1665 10500 10600 60 36 4 60 34 4 60 120 30 60 68% 70% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
14 1694 10400 10600 74 22 4 70 26 4 30 60 15 30 68% 70% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
15 2400 6500 7100 60 38 2 58 40 2 50 100 30 60 60% 68% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
16 2064 9500 9100 58 38 6 60 34 4 40 76 30 52 58% 65% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
17 1516 9600 9700 62 32 6 60 34 4 35 70 25 56 65% 68% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
18 2004 9400 9500 54 44 2 52 46 2 22 45 15 30 61% 65% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
19 2202 9000 9200 58 40 2 66 31 3 30 60 9 18 61% 68% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
20 2473 8900 9000 60 33 7 63 34 3 59 95 30 70 72% 74% NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL
HAEMATOLOGICAL INVESTIGATIONS AND URINE ANALYSIS OF IP PATIENTS
S.No IP.No
Haematological Investigation Urine Analaysis
BT AT BT AT BT
WBC Total WBS Differential Count Cu m.m E.S.R mm/hr HB BT AT
Sug DepAT
Motion Analaysis
BT AT
Ova Cyst
AT - After TreatmentBT - Berfore Treatment
Ova CystBT AT Alb Sug Dep Alb
P S MS MR
1 63424 Vijaya lakshmi 61/F 30.11.09 11.12.09 19 + + + - Improved
2 33921 Santhi 40/F 18.06.09 09.12.09 155 + + + + Partially Improved
3 33854 rajeswari 52/F 18.06.09 06.11.09 141 + + + - Partially Improved
4 35371 Parvathi 50/F 27.06.09 28.10.09 123 + + + - Partially Improved
5 48643 Sellammal 49/F 04.09.09 26.11.09 83 + + - - Improved
6 50925 Jayakili 45/F 17.09.09 08.10.09 22 + - + -  Improved
7 63269 Valliammal 35/F 24.11.09 09.12.09 16 + + - - Partially Improved
8 40304 Andhoniammal 45/F 23.07.2009 15.10.09 84 + - + - Partially Improved
9 37465 Indhirani 52/F 08.07.2009 11.09.09 96 + - + - Improved
10 51850 Saroja 54/F 23.09.09 04.11.09 42 + - + +  Improved
11 46522 Gomathirajan 55/F 24.08.09 10.09.09 18 + - - - Partially Improved
12 35133 Pichiah Pillai 53/M 25.06.09 26.11.09 153 + + + + Nil
13 36433 Saroja 60/F 03.07.09 23.09.09 82 + - + -  Improved
14 42832 Pechiammal 52/F 05.08.09 25.08.09 20 + + - - Partially Improved
15 41229 RashithaBegam 45/F 26.07.2009 15.12.09 140 + + + +  Improved
16 67410 Bala 23/F 15.12.09 28.12.09 14 + - + - Nil
17 67174 Mariam Beevi 34/F 14.12.09 27.12.09 14 + + - - Partially Improved
18 67084 Barathi 63/F 17.12.09 27.12.09 11 + - + - Nil
19 67143 Maniammal 70/F 14.12.09 27.12.09 14 + - + -  Improved
20 57324 Najima 40/F 22.10.09 12.12.09 50 + - + - Partially Improved
P - PAIN "+"  PRESENT
S - SWELLING "- "  ABSENT
MS - MORNING STIFFNESS
MR - MOVEMENT RESTRICTION
List Of Outpatients of PG-III Sirappu Maruthuvam Department
Given 1) Meganathe mezhugu As Internal Medicine
      2) Mukkuttu ennai - External Medicine
S.NO OP.NO Name Age/Sex Date Of Registration
Symptoms
ResultsNo of days treated
Date of end of 
treatment
RA FACTOR
WBC HB Blood Serum Blood
P% L% E% 1/2 hr 1 hr Alb Sug Dep
1 63424 8200 62 34 4 4 8 74% NIL NIL NIL
2 33921 8400 54 40 6 4 8 71% NIL NIL 1-2 pus 84 245 26 Negative
3 33854 9400 73 25 2 10 25 68% NIL NIL NIL 144 192 31 Positive
4 35371 8700 68 29 3 8 15 74% NIL NIL NIL 110 178 23 Negative
5 48643 8100 69 30 1 6 12 66% NIL NIL NIL 68 199 37 Negative
6 50925 8300 60 35 5 5 10 72% NIL NIL NIL 83 216 19 Positive
7 63269 9800 70 28 2 6 12 61% NIL NIL NIL 99 157 21 Positive
8 40304 8900 64 34 2 15 30 65% NIL NIL NIL 161 241 38 Negative
9 37465 8100 65 30 5 8 15 70% NIL NIL NIL 145 210 25 Positive
10 51850 9000 55 42 3 15 35 60% NIL NIL NIL 113 159 19 Negative
11 46522 7900 67 30 3 10 25 68% NIL NIL NIL 107 223 20 Negative
12 35133 9600 60 32 8 14 28 78% NIL NIL NIL 107 199 21 Negative
13 36433 8300 55 41 4 18 30 61% NIL NIL NIL 122 165 20 Negative
14 42832 7400 66 31 3 30 60 68% NIL NIL NIL 100 199 19 Positive
15 41229 7600 55 40 5 30 60 51% NIL NIL 1-2 pus 2-3 epi 85 178 18 Positive
16 67410 9500 58 38 6 40 76 58% NIL NIL NIL 130 168 17 Positive
17 67174 9600 62 32 6 35 70 65% NIL NIL NIL 110 178 23 Negative
18 67084 7200 54 40 6 4 10 58% NIL NIL NIL 88 250 16 Positive
19 67143 9000 66 30 4 6 12 68% NIL NIL NIL 142 207 30 Negative
20 57324 7700 55 42 3 27 42 62% NIL NIL NIL 120 173 33 Positive
INVESTIGATIONS OF OP PATIENTS OF UTHERA VATHA SURONITHAM
Positive
Urine Analaysis
Investigation
79 228 17
S.No. OP.NO
Haematological Investigation
 Differential Count Cu m.m E.S.R mm/hr
